DE102011079666A1 - Hair treating agent useful e.g. for reducing dirt of skin or keratinous fibers, and care and conditioning of skin or keratinous fibers, comprises oils from seeds of cape chestnut, polymeric quaternary ammonium compound and aqueous carrier - Google Patents

Abstract

Hair treating agent comprises (in wt.%, based on the weight of the agent): (a) at least one oil from seeds of cape chestnut (yangu) (0.01); (b) at least a polymeric quaternary ammonium compound (0.1-10); and (c) an aqueous carrier. An independent claim is also included for treating skin and keratin fibers, comprising applying and distributing the above composition on the skin and/or hair, and rinsing with water after a contact time of few seconds to 45 minutes.

Description

The present invention relates to hair treatment compositions containing Yangu oil. Yangu oil is referred to as Calodendrum capense (Yangu) Oil according to the usual nomenclature for cosmetic ingredients. Yangu belongs botanically to the family of the Rutaceae. The hair treatment compositions of the present invention contain the Yangu oil as part of a drug complex.

The cosmetic treatment of skin and hair is an important part of human body care. For example, human hair is today treated in a variety of ways with hair cosmetic preparations. These include, for example, the cleansing of hair with shampoos, the care and regeneration with rinses and cures and the bleaching, dyeing and shaping of the hair with dyes, tinting agents, waving agents and styling preparations.

Skin and hair cleansers, such as those commercially available as liquid soaps, shampoos, shower baths, bubble baths, shower gels, and wash gels, must not only have good detergency, but should also be well tolerated by the skin and mucous membranes as well if used frequently, do not cause excessive defatting or dryness. In addition, the consumer judges the performance characteristics but also on the amount and quality of the foam forming in the application, after the care effect and the freshness feeling.

The cleaning and care of dry skin is an even greater problem. Due to the usually high surfactant content especially the dry skin is even more stressed. Due to the high surfactant content of the dry skin lipids are largely removed. As a result, this skin type dries even more, becoming brittle, cracked and flaky. This appearance is evident both on the body and on the scalp. Usually, cleaning agents for use on dry skin are therefore added refatting substances. However, these in turn lead to a significantly weaker foam development of the products. This gives the consumer the impression that these detergents would not clean sufficiently.

Usually, it is attempted to counteract the further drying out of dry skin by adding lipid-replenishing or moisturizing agents, such as glycerine or water-binding hydrating substances, to the compositions. However, the keratolytic reaction of the dry skin caused by the surfactants is not prevented.

An ingredient which can be used in principle in cosmetic compositions, but has not found widespread use in cosmetic compositions, is the oil obtained from the seeds of the capercastia.

Surprisingly, it has now been found that an oil, which is obtained from the seeds of the Kapkastanie, is excellently suited to be used in cosmetic compositions. The surprising effects are particularly evident when an oil from the seeds of the Kapkastanie is used together with at least one ester oil.

• a. mindestens 0,01 Gew.-% eines oder mehrerer Öle, gewonnen aus Samen der Kapkastanie (Calodendrum capense; Yangu),
• b. 0,1 bis 10,0 Gew.-% mindestens einer polymeren quartären Ammoniumverbindung,
• c. einen wässrigen Träger.

A first subject of the present invention is therefore a hair treatment composition containing - based on its weight -

• a. at least 0.01% by weight of one or more oils obtained from the seeds of the capercaillie (Calodendrum capense; Yangu),
• b. 0.1 to 10.0% by weight of at least one polymeric quaternary ammonium compound,
• c. an aqueous carrier.

Hair treatment compositions for the purposes of the present invention are, for example, hair dyes, bleaching agents, hair shampoos, hair conditioners, conditioning shampoos, hair sprays, hair rinses, hair treatments, hair wraps, hair tonics, perming solutions, hair dye shampoos, hair dyes, hair fixatives, hair dressings, hair styling preparations, hair lotions , Mousse, hair gels, hair waxes or combinations thereof. In view of the fact that the consumer, but in particular men often shy away from the use of several different means and / or several application steps, means according to the invention are preferably those means which the consumer, in particular the man applies anyway. Preferred agents according to the invention are therefore shampoos, conditioners or hair tonics.

As ingredient a), the compositions according to the invention contain at least one oil which is obtained from the seeds of the cape chestnut. The Kapkastanie is the only kind from the kind Calodendrum, which belongs to the family of the Rutaceae (Rautengewächse). The oil from the chestnuts is commercially available as Yangu oil.

The oil from the seeds of the Kapkastanie is in preferred compositions according to invention in quantities from 0.05 to 10 Gew. -%, prefers 0.075 to 7.5 Gew. -% more prefers 0.1 to 5 Gew. -%, particularly prefers 0 , 15 to 2.5 wt .-% and in particular 0.2 to 1 wt .-%.

As second ingredients, the compositions according to the invention contain, based on their weight, from 0.1 to 10.0% by weight of at least one polymeric quaternary ammonium compound. These compounds are also referred to hereinafter as "cationic polymers".

Among the cationic polymers that can be included in the inventive composition, for example vinylpyrrolidone / dimethylaminoethyl copolymer available under the trade names Gafquat ^® 755 N and Gafquat ^® 734, United States is marketed by Gaf Co. and of which the Gafquat ^® 734 is particularly preferred suitable. Other cationic polymers are, for example, Germany, marketed by the company BASF under the tradename Luviquat ^® HM 550 copolymer of polyvinyl pyrrolidone and imidazolimine which ^® by the company Calgon / USA under the trade name Merquat Plus 3300 sold terpolymer of dimethyldiallylammonium chloride, sodium acrylate and acrylamide and sold by the company ISP under the trade name Gafquat ^® HS 100 vinylpyrrolidone / methacrylamidopropyltrimethylammonium chloride copolymer.

• – R¹ steht für eine Methylgruppe
• – R², R³ und R⁴ stehen für Methylgruppen
• – m hat den Wert 2.

Homopolymers of the general formula (P1), - {CH ₂ - [CR ¹ COO- (CH _{2) m} N ⁺ R ² R ³ R ^4] _n X} ^- (P1) in which R ¹ = -H or -CH ₃ ,
R ² , R ³ and R ^{4 are} independently selected from C 1-4 -alkyl, -alkenyl or -hydroxyalkyl groups,
m = 1, 2, 3 or 4,
n is a natural number and
X ^{- is} a physiologically acceptable organic or inorganic anion, and copolymers consisting essentially of the monomer units listed in formula (monomer-3) and nonionic monomer units, are particularly preferred cationic polymers. In the context of these polymers, preference is given to those according to the invention for which at least one of the following conditions applies:

• - R ¹ is a methyl group
• - R ² , R ³ and R ⁴ are methyl groups
• - m has the value 2.

Suitable physiologically tolerated counterions X ^- include, for example, halide ions, sulfate ions, phosphate ions, methosulfate ions and organic ions such as lactate, citrate, tartrate and acetate ions. Preference is given to halide ions, in particular chloride.

A particularly suitable homopolymer is, if desired, crosslinked, poly (methacryloyloxyethyltrimethylammonium chloride) with the INCI name Polyquaternium-37. Such products are available, for example under the names Rheocare ^® CTH (Cosmetic Rheologies) and Synthalen® ^® CR (3V Sigma) in trade. If desired, the crosslinking can be carried out with the aid of poly olefinically unsaturated compounds, for example divinylbenzene, tetraallyloxyethane, methylenebisacrylamide, diallyl ether, polyallylpolyglyceryl ethers, or allyl ethers of sugars or sugar derivatives such as erythritol, pentaerythritol, arabitol, mannitol, sorbitol, sucrose or glucose. Methylenebisacrylamide is a preferred crosslinking agent.

The homopolymer is preferably used in the form of a nonaqueous polymer dispersion which should not have a polymer content of less than 30% by weight. Such polymer dispersions are (under the names Salcare ^® SC 95 about 50% polymer content, additional components: mineral oil (INCI name: Mineral Oil) and tridecyl-polyoxypropylene-polyoxyethylene-ether (INCI name: PPG-1 trideceth-6) ) and Salcare ^® SC 96 (about 50% polymer content, additional components: mixture of diesters of propylene glycol (with a mixture of caprylic and capric acid INCI name: propylene glycol Dicaprylate / Dicaprate) and Tridecylpolyoxypropylen polyoxyethylene ether (INCI name : PPG-1-trideceth-6)) are commercially available.

Copolymers with monomer units of the formula (Pmonomer-3) contain as nonionic monomer units preferably acrylamide, methacrylamide, acrylic acid-C _1-4 -alkyl esters and methacrylic acid-C _1-4 -alkyl esters. Among these nonionic monomers, the acrylamide is particularly preferred. These copolymers can also be crosslinked, as described above in the case of the homopolymers. A copolymer preferred according to the invention is the crosslinked acrylamide-methacryloyloxyethyltrimethylammonium chloride copolymer. Such copolymers in which the monomers are present in a weight ratio of about 20:80, are commercially available as approximately 50% non-aqueous polymer dispersion 92 under the name Salcare ^® SC.

Suitable cationic silicone compounds preferably have either at least one amino group or at least one ammonium group. Suitable silicone polymers having amino groups are known by the INCI name amodimethicones. These are polydimethylsiloxanes with aminoalkyl groups. The aminoalkyl groups may be side or terminal. The N-containing silicone cationic polymer of the present invention may preferably be selected from the group consisting of siloxane polymers having at least one amino group, siloxane polymers having at least one terminal amino group, amodimethicone, trimethylsilylamodimethicone, and / or aminoethylaminopropylsiloxane-dimethylsiloxane copolymer. Suitable silicone polymers having two terminal quaternary ammonium groups are known by the INCI name Quaternium-80. These are dimethylsiloxanes having two terminal aminoalkyl groups.

wobei R = OH oder CH₃; X = Alkylgruppe mit 1 bis 4 C-Atomen, vorzugsweise Propyl oder Isopropyl und A, B und C = Copolymereinheiten, die taktische und/oder ataktische Polymerblöcke ausbilden können, sind.Preferred according to the invention is the use of an aminosiloxane according to the following general formula (P-2),

wherein R = OH or CH ₃ ; X = alkyl group having 1 to 4 C atoms, preferably propyl or isopropyl, and A, B and C = copolymer units which can form tactical and / or atactic polymer blocks.

Amodimethicone, amodimethicone-containing emulsions or fluids are most preferred according to the invention. Emulsions which can preferably be used according to the invention are Dow ^Corning® 949, which is a cationic emulsion comprising amodimethicone, cetrimonium chloride and trideceth-12; Dow ^Corning® 939, which is an emulsion containing amodimethicone, cetrimonium chloride and trideceth-12; Dow ^Corning® 929, which is a cationic emulsion containing amodimethicone, talc trimonium chloride and nonoxynol-10; Dow Corning ^® 7224 or 1401 based on trimethylsilylamodimethicone, octoxynol-40, Isolaureth-6, and glycol; Dow Corning ^® 2-8194 Microemulsion (26%) are based on an amine functional silicone polymer; Dow Corning ^® 2-8177 Microemulsion (12%) are based on an amine functional silicone polymer; Dow Corning ^® 2-8566 Amino Fluid based on an amine functional polydimethylsiloxane; available from Dow Corning.

The molecular weight of the aminosilicones is preferably between 500 and 100,000. The amine content (meq / g) is preferably in the range from 0.05 to 2.3, more preferably from 01 to 0.5.

The aminosilicone cationic polymer of the invention is used in an amount of 0.01 to 20 wt .-% based on the total agent, preferably in amounts of 0.05 to 15 wt .-% and most preferably in amounts of 0.05 to 10 wt .-% used.

Suitable cationic polymers derived from natural polymers are cationic derivatives of polysaccharides, for example, cationic derivatives of cellulose, starch or guar. Also suitable are chitosan and chitosan derivatives. Cationic polysaccharides have the general formula (P-3) GOBN + R _a R _b R _c X ^-
G is an anhydroglucose residue, for example starch or cellulose anhydroglucose;
B is a divalent linking group, for example, alkylene, oxyalkylene, polyoxyalkylene or hydroxyalkylene;
R _a , R _b and R _c are independently alkyl, aryl, alkylaryl, arylalkyl, alkoxyalkyl or alkoxyaryl each having up to 18 carbon atoms, wherein the total number of carbon atoms in R _a , R _b and R _{c is} preferably not more than 20 is;
X ^- is a common counteranion and is preferably chloride.

A cationic cellulose is sold under the name Polymer JR 400 from Amerchol ^® and has the INCI designation Polyquaternium-10 degrees. Another cationic cellulose bears the INCI name Polyquaternium-24 and is sold under the trade name Polymer LM-200 by Amerchol. Other commercial products are the compounds Celquat ^® H 100, Celquat ^® L and 200. The commercial products mentioned are preferred cationic celluloses.

Suitable cationic guar derivatives are marketed under the trade name Jaguar ^® and have the INCI name guar hydroxypropyltrimonium chloride. Further particularly suitable cationic guar derivatives are also used by the company. Hercules under the name N-Hance ^® commercially. Other cationic guar derivatives are marketed by the company. Cognis under the name Cosmedia® ^®. A preferred cationic guar derivative is the commercial product AquaCat® ^® from. Hercules. This raw material is an already pre-dissolved cationic guar derivative.

Another particularly useful cationic natural polymer is chitosan type hydrocolloids. Unlike most hydrocolloids, which are negatively charged at biological pH levels, chitosans are cationic biopolymers under these conditions.

The positively charged chitosans can interact with oppositely charged surfaces and are therefore used in cosmetic hair and body care products as a film former. In addition to the chitosans are also quaternized, alkylated and / or hydroxyalkylated derivatives, optionally also in microcrystalline form into consideration. The insert can also be in the form of aqueous gels having a solids content in the range of 1 to 5 wt .-%.

The chitosans to be used according to the invention are completely or partially deacetylated chitins. The molecular weight of the chitosan can be distributed over a broad spectrum, for example from 20,000 to about 5 million g / mol. For example, a low molecular weight chitosan having a molecular weight of from 30,000 to 70,000 g / mol is suitable. Preferably, however, the molecular weight is above 100,000 g / mol, more preferably from 200,000 to 700,000 g / mol. The degree of deacetylation is preferably 10 to 99%, more preferably 60 to 99%.

The chitosans or chitosan derivatives are preferably in neutralized or partially neutralized form. The degree of neutralization of the chitosan or the chitosan derivative is preferably at least 50%, more preferably between 70 and 100%, based on the number of free base groups. As a neutralizing agent, in principle, all cosmetically acceptable inorganic or organic acids can be used such as formic acid, tartaric acid, malic acid, lactic acid, citric acid, pyrrolidonecarboxylic acid, hydrochloric acid u. a., Of which the pyrrolidonecarboxylic acid is particularly preferred.

A suitable chitosan is sold, for example, by Kyowa Oil & Fat, Japan under the trade name Flonac ^®. It has a molecular weight of 300,000 to 700,000 g / mol and is deacetylated to 70 to 80%. A preferred chitosan is chitosoniumpyrrolidone is, for example, sold under the name Kytamer ^® PC by Amerchol, USA. The contained chitosan has a molecular weight of about 200,000 to 300,000 g / mol and is deacetylated to 70 to 85%. Suitable chitosan derivatives are quaternized, alkylated or hydroxyalkylated derivatives, for example hydroxyethyl or hydroxybutylchitosan. Further chitosan derivatives are Hydagen® ^® CMF, Hydagen® ^® HCMF and Chitolam ^® NB / 101 freely available under the trade names in the trade.

• – quaternisierte Cellulose-Derivate, wie sie unter den Bezeichnungen Celquat^® und Polymer JR^® im Handel erhältlich sind. Die Verbindungen Celquat^® H 100, Celquat^® L 200 und Polymer JR^®400 sind bevorzugte quaternierte Cellulose-Derivate,
• – kationische Alkylpolyglycoside gemäß der DE-PS 44 13 686 ,
• – kationisierter Honig, beispielsweise das Handelsprodukt Honeyquat^® 50,
• – kationische Guar-Derivate, wie insbesondere die unter den Handelsnamen Cosmedia^® Guar und Jaguar^® vertriebenen Produkte,
• – polymere Dimethyldiallylammoniumsalze und deren Copolymere mit Estern und Amiden von Acrylsäure und Methacrylsäure. Die unter den Bezeichnungen Merquat^®100 (Poly(dimethyldiallylammoniumchlorid)) und Merquat^®550 (Dimethyldiallylammoniumchlorid-Acrylamid-Copolymer) im Handel erhältlichen Produkte sind Beispiele für solche kationischen Polymere,
• – Copolymere des Vinylpyrrolidons mit quaternierten Derivaten des Dialkylaminoalkylacrylats und -methacrylats, wie beispielsweise mit Diethylsulfat quaternierte Vinylpyrrolidon-Dimethylaminoethylmethacrylat-Copolymere. Solche Verbindungen sind unter den Bezeichnungen Gafquat^®734 und Gafquat^®755 im Handel erhältlich,
• – Vinylpyrrolidon-Vinylimidazoliummethochlorid-Copolymere, wie sie unter den Bezeichnungen Luviquat^® FC 370, FC 550, FC 905 und HM 552 angeboten werden,
• – quaternierter Polyvinylalkohol,
• – sowie die unter den Bezeichnungen Polyquaternium 2, Polyquaternium 17, Polyquaternium 18 und Polyquaternium 27 bekannten Polymeren mit quartären Stickstoffatomen in der Polymerhauptkette,
• – Vinylpyrrolidon-Vinylcaprolactam-Acrylat-Terpolymere, wie sie mit Acrylsäureestern und Acrylsäureamiden als dritter Monomerbaustein im Handel beispielsweise unter der Bezeichnung Aquaflex^® SF 40 angeboten werden.

Further preferred cationic polymers are, for example

• - Quaternized cellulose derivatives, such as those under the names Celquat ^® and Polymer JR ^® commercially available. The compounds Celquat ^® H 100, Celquat L 200 and Polymer JR ^{® ®} 400 are preferred quaternized cellulose derivatives
• Cationic alkyl polyglycosides according to DE-PS 44 13 686 .
• - cationized honey, for example the commercial product Honeyquat ^® 50,
• - cationic guar derivatives, such as in particular the products sold under the trade names Cosmedia® ^® Guar and Jaguar ^®,
• - Dimethyldiallylammoniumsalze polymeric and their copolymers with esters and amides of acrylic acid and methacrylic acid. Under the names Merquat ^® 100 (Poly (dimethyldiallylammonium chloride)) and Merquat ^® 550 (dimethyldiallylammonium chloride-acrylamide copolymer) are examples of such cationic polymers,
• - Copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acrylate and methacrylate, such as diethyl sulfate quaternized vinylpyrrolidone-dimethylaminoethyl methacrylate copolymers. Such compounds are sold under the names Gafquat ^® 734 and Gafquat ^® 755 commercially,
• - vinylpyrrolidone vinylimidazoliummethochloride copolymers, such as those offered under the names Luviquat.RTM ^® FC 370, FC 550, FC 905 and HM 552,
• - quaternized polyvinyl alcohol,
• - as well as the polymers known under the names Polyquaternium 2, Polyquaternium 17, Polyquaternium 18 and Polyquaternium 27 with quaternary nitrogen atoms in the polymer main chain,
• - Vinylpyrrolidone-vinylcaprolactam-acrylate terpolymers, such as those with acrylic acid esters and acrylic acid amides as a third monomer building commercially available, for example, under the name Aquaflex ^® SF 40.

Can be used as cationic polymers are sold under the names Polyquaternium-24 (commercial product z. B. Quatrisoft ^® LM 200), known polymers. , Gaffix ^® VC 713 (manufactured by ISP): Also according to the invention can be used the copolymers of vinylpyrrolidone, such as the commercial products Copolymer 845 (ISP manufacturer) are Gafquat ^® ASCP 1011, Gafquat ^® HS 110, Luviquat ^® 8155 and Luviquat ^® MS 370 available are.

Other cationic polymers which can be used in the compositions according to the invention are the so-called "temporary cationic" polymers. These polymers usually contain an amino group which, at certain pH values, is present as quaternary ammonium group and thus cationic. For example, chitosan and its derivatives are preferred as Hydagen CMF ^®, Hydagen HCMF ^®, Kytamer ^® PC and Chitolam ^® NB / 101 are freely available commercially, for example under the trade names.

According to the invention preferred cationic polymers are cationic cellulose derivatives and chitosan and its derivatives, in particular the commercial products Polymer JR 400, Hydagen ^® HCMF and Kytamer ^® PC, cationic guar derivatives, cationic honey derivatives, in particular the commercial product Honeyquat ^® 50, cationic Alkylpolyglycodside according of the DE-PS 44 13 686 and polyquaternium-37 type polymers.

• – Poly(methacryloyloxyethyltrimethylammoniumverbindungen) und/oder
• – quaternisierten Cellulose-Derivaten, insbesondere Polyquaternium 10 und/oder Polyquaternium 67, und/oder
• – kationischen Guar-Derivaten und/oder
• – Chitosan und/oder
• – polymeren Dimethyldiallylammoniumsalzen und deren Copolymeren mit Estern und Amiden von Acrylsäure und Methacrylsäure und/oder
• – Copolymeren des Vinylpyrrolidons mit quaternierten Derivaten des Dialkylaminoalkylacrylats und -methacrylats und/oder
• – Vinylpyrrolidon-Vinylimidazoliummethochlorid-Copolymeren und/oder
• – quaterniertem Polyvinylalkohol und/oder
• – Polyquaternium 2 und/oder
• – Polyquaternium-7 und/oder
• – Polyquaternium-16 und/oder
• – Polyquaternium 17 und/oder
• – Polyquaternium 18 und/oder
• – Polyquaternium 24 und/oder
• – Polyquaternium 27

enthalten.In summary, preferred hair treatment compositions according to the invention are characterized in that they contain 0.15 to 7.5% by weight, more preferably 0.2 to 5% by weight, more preferably 0.25 to 2.5% by weight and in particular 0, 3 to 2 wt .-% of one or more polymeric quaternary ammonium compounds from the group

• - Poly (methacryloyloxyethyltrimethylammoniumverbindungen) and / or
• Quaternized cellulose derivatives, in particular Polyquaternium 10 and / or Polyquaternium 67, and / or
• Cationic guar derivatives and / or
• - Chitosan and / or
• Polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or
• - Copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acrylate and methacrylate and / or
• - Vinylpyrrolidone-Vinylimidazoliummethochlorid copolymers and / or
• Quaternized polyvinyl alcohol and / or
• Polyquaternium 2 and / or
• Polyquaternium-7 and / or
• Polyquaternium-16 and / or
• - Polyquaternium 17 and / or
• - Polyquaternium 18 and / or
• - Polyquaternium 24 and / or
• - Polyquaternium 27

contain.

It has been found preferable to additionally use protein hydrolyzates in the agents according to the invention, since this further enhances the care effects. Surprisingly, protein hydrolysates of animal origin have been found to be much more potent, so that preferred agents according to the invention contain at least one protein hydrolyzate of animal origin.

Examples of sources of proteins of animal origin are collagen, milk or keratin or proteins such as fish collagen. Animal protein hydrolysates are, for example, elastin, collagen, keratin, silk and milk protein protein hydrolysates, which may also be present in the form of salts. Such products are, for example, under the trademarks Dehylan ^® (Cognis), Promois® ^® (Interorgana) Collapuron ^® (Cognis), Nutrilan® ^® (Cognis), Gelita-Sol ^® (German Gelatinefabriken Stoess & Co), Lexein ^® (Inolex) and kerasol tm ^® (Croda) sold.

Very particular preference is given to using keratin hydrolysates according to the invention.

Keratin is understood here as structural proteins which form the intermediate filaments in epithelial and epidermis cells, the so-called keratinocytes, as constituents of the cytoskeleton and the resulting horny substances of the skin and skin appendages, especially hair, scales, wool, feathers, nails and Hooves, make out. The keratins can be obtained from natural sources or produced recombinantly.

Preferably, the agent contains at least one keratin hydrolyzate having a molecular weight of from 400 to 6500 Da, preferably from 400 to 3000 Da.

Depending on the molecular weights of the amino acids of which the keratin is made up, the keratin hydrolysates may contain a few to less than a hundred amino acids. The agents preferably contain keratin hydrolysates which have 2 to 50 amino acids, preferably 4 to 45 amino acids, particularly preferably 5 to 40 amino acids.

Preference is given to keratin hydrolysates which have a content of L-cysteine of from 2 to 6 mol%, preferably from 4 to 5 mol%. Particularly preferred are keratin hydrolysates containing 2 to 6 mol% L-cysteine, 1 to 40 mol% glycine and 1 to 30 wt% serine.

Preferably, the agent contains keratin hydrolyzate (s) in an amount of 0.1 to 4 wt .-%, preferably from 0.3 to 3 wt .-%, particularly preferably from 0.5 to 1 wt .-%. The percentages in each case relate to the weight of the entire composition.

In summary, preferred hair treatment compositions according to the invention are characterized in that they contain 0.15 to 7.5% by weight, more preferably 0.2 to 5% by weight, more preferably 0.25 to 2.5% by weight and in particular 0, 3 to 2 wt .-% of at least one protein hydrolyzate of animal origin, wherein preferred means 0.15 to 7.5 wt .-%, more preferably 0.2 to 5 wt .-%, particularly preferably 0.25 to 2.5 wt .-% and in particular 0.3 to 2 wt .-% Keratinhydrolysat (s) included.

Instead of the keratin hydrolysates or preferably in addition to them, one or more amino acids can additionally be used in the agents according to the invention, since this can further enhance the care effects.

As a further ingredient, the agents according to the invention may with particular preference contain one or more amino acids. Amino acids which can be used particularly preferably according to the invention are selected from the group glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-sulfoxide (L-alliin), L-trans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.

Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here, preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1.5 Wt .-%, more preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt. % Amino acid (s), preferably from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.

It is particularly preferred according to the invention if the agents contain at least one amino acid from the group taurine, proline, valine, arginine, lysine and glycine. In the agents according to the invention, the use of several amino acids from the abovementioned group is preferred. Particularly preferred agents according to the invention are characterized in that they contain at least two, preferably at least three, more preferably at least four, more preferably at least five and in particular all six amino acid from the group taurine, proline, valine, arginine, lysine and glycine.

• – Yangu-Öl und Taurin,
• – Yangu-Öl und Prolin,
• – Yangu-Öl und Valin,
• – Yangu-Öl und Arginin,
• – Yangu-Öl und Lysin,
• – Yangu-Öl und Glycin,
• – Yangu-Öl und Taurin und Prolin,
• – Yangu-Öl und Taurin und Valin,
• – Yangu-Öl und Taurin und Arginin,
• – Yangu-Öl und Taurin und Lysin,
• – Yangu-Öl und Taurin und Glycin,
• – Yangu-Öl und Prolin und Valin,
• – Yangu-Öl und Prolin und Arginin,
• – Yangu-Öl und Prolin und Lysin,
• – Yangu-Öl und Prolin und Glycin,
• – Yangu-Öl und Valin und Arginin,
• – Yangu-Öl und Valin und Lysin,
• – Yangu-Öl und Valin und Glycin,
• – Yangu-Öl und Arginin und Lysin,
• – Yangu-Öl und Arginin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Valin,
• – Yangu-Öl und Taurin und Prolin und Arginin,
• – Yangu-Öl und Taurin und Prolin und Lysin,
• – Yangu-Öl und Taurin und Prolin und Glycin,
• – Yangu-Öl und Taurin und Valin und Lysin,
• – Yangu-Öl und Taurin und Valin und Glycin,
• – Yangu-Öl und Taurin und Arginin und Lysin,
• – Yangu-Öl und Taurin und Arginin und Glycin,
• – Yangu-Öl und Taurin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Valin und Arginin,
• – Yangu-Öl und Taurin und Valin und Lysin,
• – Yangu-Öl und Taurin und Valin und Glycin,
• – Yangu-Öl und Prolin und Valin und Arginin,
• – Yangu-Öl und Prolin und Valin und Lysin,
• – Yangu-Öl und Prolin und Valin und Glycin,
• – Yangu-Öl und Prolin und Arginin und Lysin,
• – Yangu-Öl und Prolin und Arginin und Glycin,
• – Yangu-Öl und Valin und Arginin und Lysin,
• – Yangu-Öl und Valin und Arginin und Glycin,
• – Yangu-Öl und Arginin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Valin und Arginin,
• – Yangu-Öl und Taurin und Prolin und Valin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Valin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Prolin und Valin und Arginin und Lysin,
• – Yangu-Öl und Prolin und Valin und Arginin und Glycin,
• – Yangu-Öl und Prolin und Valin und Lysin und Glycin,
• – Yangu-Öl und Prolin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Valin und Arginin und Lysin,
• – Yangu-Öl und Taurin und Valin und Arginin und Glycin,
• – Yangu-Öl und Taurin und Valin und Lysin und Glycin,
• – Yangu-Öl und Taurin und und Arginin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Arginin und Lysin,
• – Yangu-Öl und Taurin und Prolin und Arginin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Valin und Arginin und Lysin,
• – Yangu-Öl und Taurin und Prolin und Valin und Arginin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Valin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Valin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Prolin und Valin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Taurin und Prolin und Valin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin,
• – Yangu-Öl und Keratinhydrolysat(e) und Valin,
• – Yangu-Öl und Keratinhydrolysat(e) und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Valin und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Valin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Valin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Valin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Valin und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Valin und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Valin und Arginin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Valin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Valin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Valin und Arginin und Lysin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Valin und Arginin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Valin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Valin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Prolin und Valin und Arginin und Lysin und Glycin,
• – Yangu-Öl und Keratinhydrolysat(e) und Taurin und Prolin und Valin und Arginin und Lysin und Glycin,

Very particularly preferred agents according to the invention

• - Yangu oil and taurine,
• - Yangu oil and proline,
• - Yangu oil and valine,
• - Yangu oil and arginine,
• - Yangu oil and lysine,
• - Yangu oil and glycine,
• - Yangu oil and taurine and proline,
• - Yangu oil and taurine and valine,
• - Yangu oil and taurine and arginine,
• - Yangu oil and taurine and lysine,
• - Yangu oil and taurine and glycine,
• - Yangu oil and proline and valine,
• - Yangu oil and proline and arginine,
• - Yangu oil and proline and lysine,
• - Yangu oil and proline and glycine,
• - Yangu oil and valine and arginine,
• - Yangu oil and valine and lysine,
• - Yangu oil and valine and glycine,
• - Yangu oil and arginine and lysine,
• - Yangu oil and arginine and glycine,
• - Yangu oil and taurine and proline and valine,
• - Yangu oil and taurine and proline and arginine,
• - Yangu oil and taurine and proline and lysine,
• - Yangu oil and taurine and proline and glycine,
• - Yangu oil and taurine and valine and lysine,
• - Yangu oil and taurine and valine and glycine,
• - Yangu oil and taurine and arginine and lysine,
• - Yangu oil and taurine and arginine and glycine,
• - Yangu oil and taurine and lysine and glycine,
• - Yangu oil and taurine and valine and arginine,
• - Yangu oil and taurine and valine and lysine,
• - Yangu oil and taurine and valine and glycine,
• - Yangu oil and proline and valine and arginine,
• - Yangu oil and proline and valine and lysine,
• - Yangu oil and proline and valine and glycine,
• - Yangu oil and proline and arginine and lysine,
• - Yangu oil and proline and arginine and glycine,
• - Yangu oil and valine and arginine and lysine,
• - Yangu oil and valine and arginine and glycine,
• - Yangu oil and arginine and lysine and glycine,
• - Yangu oil and taurine and proline and valine and arginine,
• - Yangu oil and taurine and proline and valine and glycine,
• - Yangu oil and taurine and proline and lysine and glycine,
• - Yangu oil and taurine and arginine and lysine and glycine,
• - Yangu oil and valine and arginine and lysine and glycine,
• - Yangu oil and proline and valine and arginine and lysine,
• - Yangu oil and proline and valine and arginine and glycine,
• - Yangu oil and proline and valine and lysine and glycine,
• - Yangu oil and proline and arginine and lysine and glycine,
• - Yangu oil and taurine and valine and arginine and lysine,
• - Yangu oil and taurine and valine and arginine and glycine,
• - Yangu oil and taurine and valine and lysine and glycine,
• - Yangu oil and taurine and and arginine and lysine and glycine,
• - Yangu oil and taurine and proline and arginine and lysine,
• - Yangu oil and taurine and proline and arginine and glycine,
• - Yangu oil and taurine and proline and valine and arginine and lysine,
• - Yangu oil and taurine and proline and valine and arginine and glycine,
• - Yangu oil and taurine and proline and valine and lysine and glycine,
• - Yangu oil and taurine and proline and arginine and lysine and glycine,
• - Yangu oil and taurine and valine and arginine and lysine and glycine,
• - Yangu oil and proline and valine and arginine and lysine and glycine,
• - Yangu oil and taurine and proline and valine and arginine and lysine and glycine,
• Yangu oil and keratin hydrolyzate (s) and taurine,
• Yangu oil and keratin hydrolyzate (s) and proline,
• Yangu oil and keratin hydrolyzate (s) and valine,
• Yangu oil and keratin hydrolyzate (s) and arginine,
• Yangu oil and keratin hydrolyzate (s) and lysine,
• Yangu oil and keratin hydrolyzate (s) and glycine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and arginine,
• Yangu oil and keratin hydrolyzate (s) and taurine and lysine,
• Yangu oil and keratin hydrolyzate (s) and taurine and glycine,
• Yangu oil and keratin hydrolyzate (s) and proline and valine,
• Yangu oil and keratin hydrolyzate (s) and proline and arginine,
• Yangu oil and keratin hydrolyzate (s) and proline and lysine,
• Yangu oil and keratin hydrolyzate (s) and proline and glycine,
• - Yangu oil and keratin hydrolyzate (s) and valine and arginine,
• - Yangu oil and keratin hydrolyzate (s) and valine and lysine,
• Yangu oil and keratin hydrolyzate (s) and valine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and arginine and lysine,
• Yangu oil and keratin hydrolyzate (s) and arginine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and proline and valine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and arginine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and lysine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and lysine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and arginine and lysine,
• Yangu oil and keratin hydrolyzate (s) and taurine and arginine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and arginine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and lysine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and glycine,
• Yangu oil and keratin hydrolyzate (s) and proline and valine and arginine,
• Yangu oil and keratin hydrolyzate (s) and proline and valine and lysine,
• Yangu oil and keratin hydrolyzate (s) and proline and valine and glycine,
• Yangu oil and keratin hydrolyzate (s) and proline and arginine and lysine,
• Yangu oil and keratin hydrolyzate (s) and proline and arginine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and valine and arginine and lysine,
• Yangu oil and keratin hydrolyzate (s) and valine and arginine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and arginine and lysine and glycine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and valine and arginine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and valine and glycine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and arginine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and valine and arginine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and proline and valine and arginine and lysine,
• Yangu oil and keratin hydrolyzate (s) and proline and valine and arginine and glycine,
• Yangu oil and keratin hydrolyzate (s) and proline and valine and lysine and glycine,
• Yangu oil and keratin hydrolyzate (s) and proline and arginine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and arginine and lysine,
• Yangu oil and keratin hydrolyzate (s) and taurine and valine and arginine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and and arginine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and proline and arginine and lysine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and arginine and glycine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and valine and arginine and lysine
• - Yangu oil and keratin hydrolyzate (s) and taurine and proline and valine and arginine and glycine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and valine and lysine and glycine,
• Yangu oil and keratin hydrolyzate (s) and taurine and proline and arginine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and valine and arginine and lysine and glycine,
• Yangu oil and keratin hydrolyzate (s) and proline and valine and arginine and lysine and glycine,
• - Yangu oil and keratin hydrolyzate (s) and taurine and proline and valine and arginine and lysine and glycine,

In summary, preferred hair treatment compositions according to the invention are characterized in that they contain 0.02 to 2.5 wt .-%, preferably 0.05 to 1.5 wt .-%, particularly preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.

The cosmetic compositions preferably further contain at least one member selected from the group consisting of anionic, amphoteric, zwitterionic, nonionic, cationic surfactants or mixtures thereof, water-insoluble oil components, vitamins, provitamins, plant extracts, UV filters, amino acids, water-insoluble silicones, the water-soluble silicones and / or the amodimethicones

Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight and in particular from 5 to 25% by weight of anionic and / or nonionic (s) and / or cationic and / or amphoteric surfactant (s).

• – lineare und verzweigte Fettsäuren mit 8 bis 30 C-Atomen (Seifen),
• – Ethercarbonsäuren der Formel R-O-(CH₂-CH₂O)_xCH₂-COOH, in der R eine lineare Alkylgruppe mit 8 bis 30 C-Atomen und x = 0 oder 1 bis 16 ist,
• – Acylsarcoside mit 8 bis 24 C-Atomen in der Acylgruppe,
• – Acyltauride mit 8 bis 24 C-Atomen in der Acylgruppe,
• – Acylisethionate mit 8 bis 24 C-Atomen in der Acylgruppe,
• – lineare Alkansulfonate mit 8 bis 24 C-Atomen,
• – lineare Alpha-Olefinsulfonate mit 8 bis 24 C-Atomen,
• – Alpha-Sulfofettsäuremethylester von Fettsäuren mit 8 bis 30 C-Atomen,
• – Acylglutamate der Formel (T1),
  
  in der R¹CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0, 1, 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alkanolammonium oder Glucammonium steht, beispielsweise Acylglutamate, die sich von Fettsäuren mit 6 bis 22, vorzugsweise 12 bis 18 Kohlenstoffatomen ableiten, wie beispielsweise C_12/14- bzw. C_12/18-Kokosfettsäure, Laurinsäure, Myristinsäure, Palmitinsäure und/oder Stearinsäure, insbesondere Natrium-N-cocoyl- und Natrium-N-stearoyl-L-glutamat,
• – Ester einer hydroxysubstituierten Di- oder Tricarbonsäure der allgemeinen Formel (T2),
  
  in der X = H oder eine -CH₂COOR-Gruppe ist, Y = H oder -OH ist unter der Bedingung, dass Y = H ist, wenn X = -CH₂COOR ist, R, R¹ und R² unabhängig voneinander ein Wasserstoffatom, ein Alkali- oder Erdalkalimetallkation, eine Ammoniumgruppe, das Kation einer ammoniumorganischen Base oder einen Rest Z bedeuten, der von einer polyhydroxylierten organischen Verbindung stammt, die aus der Gruppe der veretherten (C₆-C₁₈)-Alkylpolysaccharide mit 1 bis 6 monomeren Saccharideinheiten und/oder der veretherten aliphatischen (C₆-C₁₆)-Hydroxyalkylpolyole mit 2 bis 16 Hydroxylresten ausgewählt sind, unter der Maßgabe, dass wenigstens eine der Gruppen R, R¹ oder R² ein Rest Z ist,
• – Ester der Sulfobernsteinsäure oder der Sulfosuccinate der allgemeinen Formel (T3I),
  
  in der M^{( n+/n)} für n = 1 ein Wasserstoffatom, ein Alkalimetallkation, eine Ammoniumgruppe oder das Kation einer ammonium-organischen Base und für n = 2 ein Erdalkalimetallkation darstellt und R¹ und R² unabhängig voneinander ein Wasserstoffatom, ein Alkali- oder Erdalkalimetallkation, eine Ammoniumgruppe, das Kation einer ammonium-organischen Base oder einen Rest Z bedeuten, der von einer polyhydroxylierten organischen Verbindung stammt, die aus der Gruppe der veretherten (C₆-C₁₈)-Alkylpolysaccharide mit 1 bis 6 monomeren Saccharideinheiten und/oder der veretherten aliphatischen (C₆-C₁₆)-Hydroxyalkylpolyole mit 2 bis 16 Hydroxylresten ausgewählt ist, unter der Maßgabe, dass wenigstens eine der Gruppen R¹ oder R² ein Rest Z ist,
• – Sulfobernsteinsäuremono- und -dialkylester mit 8 bis 24 C-Atomen in der Alkylgruppe und Sulfobernsteinsäuremonoalkylpolyoxyethylester mit 8 bis 24 C-Atomen in der Alkylgruppe und 1 bis 6 Oxyethylgruppen,
• – Alkylsulfate und Alkylpolyglycolethersulfate der Formel R-(O-CH₂-CH₂)_x-OSO₃H, in der R eine bevorzugt lineare Alkylgruppe mit 8 bis 30 C-Atomen und x = 0 oder 1–12 ist,
• – gemischte oberflächenaktive Hydroxysulfonate gemäß DE-A-37 25 030 ,
• – Ester der Weinsäure und Zitronensäure mit Alkoholen, die Anlagerungsprodukte von etwa 2–15 Molekülen Ethylenoxid und/oder Propylenoxid an C_8-22-Fettalkohole darstellen,
• – Alkyl- und/oder Alkenyletherphosphate,
• – sulfatierte Fettsäurealkylenglycolester,
• – Monoglyceridsulfate und Monoglyceridethersulfate.

Suitable anionic surfactants and emulsifiers for the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups and hydroxyl groups may be present in the molecule. Examples of suitable anionic surfactants and emulsifiers are, in each case in the form of the sodium, potassium and ammonium as well as the mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group,

• - linear and branched fatty acids with 8 to 30 carbon atoms (soaps),
• Ether carboxylic acids of the formula RO- (CH ₂ -CH ₂ O) _x CH ₂ -COOH, in which R is a linear alkyl group having 8 to 30 C atoms and x = 0 or 1 to 16,
• Acylsarcosides having 8 to 24 C atoms in the acyl group,
• Acyltaurides having 8 to 24 carbon atoms in the acyl group,
• Acyl isethionates having 8 to 24 C atoms in the acyl group,
• - linear alkanesulfonates having 8 to 24 carbon atoms,
• - linear alpha-olefin sulfonates having 8 to 24 carbon atoms,
• Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 C atoms,
• Acylglutamates of the formula (T1),
  
  in which R ¹ CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, which are derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as, for example, C _12/14 or C _12/18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, in particular sodium N-cocoyl and sodium N-stearoyl-L-glutamate,
• Esters of a hydroxy-substituted di- or tricarboxylic acid of the general formula (T2),
  
  wherein X is H or a -CH ₂ COOR group, Y is H or -OH is under the condition that Y is H when X is -CH ₂ COOR, R, R ¹ and R ^{2 are} independently a hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C ₆ -C ₁₈ ) -alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C ₆ -C ₁₆ ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R, R ¹ or R ^{2 is} a radical Z,
• Esters of sulfosuccinic acid or sulfosuccinates of the general formula (T3I),
  
  in which M ^{( n + / n)} for n = 1 represents a hydrogen atom, an alkali metal cation, an ammonium group or the cation of an ammonium organic base and for n = 2 an alkaline earth metal cation and R ¹ and R ² independently of one another represent a hydrogen atom, an alkali metal cation or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group consisting of etherified (C ₆ -C ₁₈ ) -alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C ₆ -C ₁₆ ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R ¹ or R ^{2 is} a radical Z,
• Sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C atoms in the alkyl group and sulfosuccinic acid monoalkylpolyoxyethyl esters having 8 to 24 C atoms in the alkyl group and 1 to 6 oxyethyl groups,
• Alkyl sulfates and alkyl polyglycol ether sulfates of the formula R- (O-CH ₂ -CH ₂ ) _x -OSO ₃ H, in which R is a preferably linear alkyl group having 8 to 30 C atoms and x = 0 or 1-12,
• Mixed hydroxysulfonates according to DE-A-37 25 030 .
• Esters of tartaric acid and citric acid with alcohols which are adducts of about 2-15 molecules of ethylene oxide and / or propylene oxide with C _8-22 fatty alcohols,
• Alkyl and / or alkenyl ether phosphates,
• - sulfated fatty acid alkylene glycol esters,
• Monoglyceride sulfates and monoglyceride ether sulfates.

Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which in particularly preferred embodiments of an octanoyl, decanoyl, lauroyl , Myristoyl, palmitoyl and stearoyl radical, esters of tartaric acid, citric acid or succinic acid or of the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium Coco-glucosides sulfosuccinates, alkyl polyglycol ether sulfates and ether carboxylic acids having 8 to 18 carbon atoms in the alkyl group and up to 12 ethoxy groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl ester having 8 to 18 carbon atoms in the alkyl group and 1 to 6 ethoxy groups.

Zwitterionic surfactants and emulsifiers are those surface-active compounds which carry at least one quaternary ammonium group and at least one -COO ^(-) or -SO ₃ ^(-) group in the molecule. Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl 3-hydroxyethylimidazolines each having 8 to 18 C Atoms in the alkyl or acyl group and the Kokosacylaminoethylhydroxyethylcarboxymethylglycinat. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Further preferred anionic surfactants are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acid salts having from 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule and sulfosuccinic acid mono- and dialkyl esters having from 8 to 18 carbon atoms in the alkyl group and sulfosuccinic acid monoalkyl polyoxyethyl esters having from 8 to 18 C atoms in the alkyl group and 1 to 6 oxyethyl groups.

Particularly preferred anionic surfactants are the alkali metal or ammonium salts of lauryl ether sulfate having a degree of ethoxylation of 2 to 4 EO.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain, based on their weight, from 0.1 to 20% by weight, preferably from 0.25 to 17.5% by weight and in particular from 5 to 15% by weight of anionic (s ) Surfactant (s), more preferably fatty alcohol ether sulfates of the formula H ₃ C- (CH ₂ ) _n - (OCH ₂ CH ₂ ) _k -OSO ₃ ^- M ⁺ in which n represents values of from 5 to 21, preferably from 7 to 19, more preferably from 9 to 17 and in particular from 11 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8 , 9 or 10, preferably 1, 2 or 3 and especially 2, and M is a cation from the group Na ⁺ , K ⁺ NH ₄ ⁺ , ½Mg ²⁺ , ½Zn ²⁺ , preferably Na ⁺ .

Zwitterionic surfactants and emulsifiers are those surface-active compounds which carry at least one quaternary ammonium group and at least one -COO ^(-) or -SO ₃ ^(-) group in the molecule. Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl 3-hydroxyethylimidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group and cocoacylaminoethylhydroxyethylcarboxymethylglycinate. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Ampholytic surfactants and emulsifiers are understood to mean those surface-active compounds which, apart from a C ₈ -C ₂₄ -alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SO ₃ H group and are capable of forming internal salts , Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C Atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C ₁₂ -C ₁₈ acylsarcosine.

• – N-Alkylglycine,
• – N-Alkylpropionsäuren,
• – N-Alkylaminobuttersäuren,
• – N-Alkyliminodipropionsäuren,
• – N-Hydroxyethyl-N-alkylamidopropylglycine,
• – N-Alkyltaurine,
• – N-Alkylsarcosine,
• – 2-Alkylaminopropionsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe,
• – Alkylaminoessigsäuren mit jeweils etwa 8 bis 24 C-Atomen in der Alkylgruppe,
• – N-Kokosalkylaminopropionat,
• – Kokosacylaminoethylaminopropionat
• – C₁₂-C₁₈-Acylsarcosin,
• – N-Alkyl-N,N-dimethylammonium-glycinate, beispielsweise Kokosalkyl-dimethylammoniumglycinat,
• – N-Acyl-aminopropyl-N,N-dimethylammoniumglycinate, beispielsweise Kokosacylaminopropyl-dimethylammoniumglycinat,
• – 2-Alkyl-3-carboxymethyl-3-hydroxyethyl-imidazoline mit jeweils 8 bis 18 C-Atomen in der Alkyl- oder Acylgruppe
• – Kokosacylaminoethylhydroxyethylcarboxymethylglycinat
• – der unter der INCI-Bezeichnung Cocamidopropyl Betain bekannten Verbindungen,
• – der unter der INCI-Bezeichnung Disodium Cocoamphodiacetate bekannten Verbindungen

enthalten, wobei bevorzugte Mittel das bzw. die amphotere(n) Tensid(e) in Mengen von 0,5 bis 9 Gew.-%, vorzugsweise von 0,75 bis 8 Gew.-% und insbesondere von 1 bis 7,5 Gew.-%, jeweils bezogen auf das gesamte Mittel, enthalten.Particularly preferred hair treatment compositions according to the invention are characterized in that they contain amphoteric surfactant (s) from the groups of

• - N-alkylglycines,
• N-alkylpropionic acids,
• N-alkylaminobutyric acids,
• N-alkyliminodipropionic acids,
• N-hydroxyethyl-N-alkylamidopropylglycines,
• N-alkyl taurines,
• N-alkyl sarcosines,
• 2-alkylaminopropionic acids each having about 8 to 24 C atoms in the alkyl group,
• Alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group,
• N-cocoalkylaminopropionate,
• - cocoacylaminoethylaminopropionate
• C ₁₂ -C ₁₈ acyl sarcosine,
• N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate,
• N-acyl-aminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyl-dimethylammonium glycinate,
• - 2-Alkyl-3-carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group
• Cocoacylaminoethylhydroxyethylcarboxymethylglycinate
• The compounds known by the INCI name cocamidopropyl betaine,
• - The known under the INCI name Disodium Cocoamphodiacetate compounds

preferred agents containing the amphoteric surfactant (s) in amounts of 0.5 to 9 wt .-%, preferably from 0.75 to 8 wt .-% and in particular from 1 to 7.5 wt .-%, each based on the total agent included.

in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen steht.Particularly preferred hair treatment agents contain as amphoteric surfactants betaines of the formula (T4)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.

These surfactants are referred to the INCI nomenclature as Amidopropylbetaine, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamidopropylbetaine. According to the invention, particular preference is given to using surfactants of the formula (T4) which are a mixture of the following representatives:
H ₃ C- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₉ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₁ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₃ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₁₅ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-
H ₃ C- (CH ₂ ) ₇ -CH = CH- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^-

Particular preference is given to using surfactants of the formula (T4) within narrower ranges of amounts. Here, agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T4).

enthalten, in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen steht.In addition to the amphoteric surfactant (s) of the formula (T4) or in its place, the hair-treatment compositions according to the invention can be used with particular preference as amphoteric surfactants betaines of the formula (T5)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.

These surfactants are referred to according to the INCI nomenclature as amphoacetates, wherein the representatives derived from coconut fatty acids are preferred and are referred to as cocoamphoactetates.

in der R für einen geradkettigen oder verzweigten, gesättigten oder ein- bzw. mehrfach ungesättigten Alkyl- oder Alkenlyrest mit 8 bis 24 Kohlenstoffatomen und M für ein Kation steht.For manufacturing reasons surfactants of this type often also contain betaines of the formula (T5a)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms and M is a cation.

These surfactants are referred to according to the INCI nomenclature as Amphodiacetate, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamphodiactetate.

According to the invention, particular preference is given to using surfactants of the formula (T5) which are a mixture of the following representatives: H ₃ C- (CH ₂ ), -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^- H ₃ C- (CH ₂ ) ₉ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^- H ₃ C- (CH _{2) 11} -C (O) -NH- (CH _{2) 2} NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^- H ₃ C- (CH ₂ ) ₁₃ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^- H ₃ C- (CH ₂ ) ₁₅ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^- H ₃ C- (CH ₂ ) ₇ -CH = CH- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^-

Particular preference is given to using surfactants of the formula (T5) within narrower ranges of amounts. Here, agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T5).

• – H₃C-(CH₂)₇
• – H₃C-(CH₂)₉-
• – H₃C-(CH₂)₁₁-
• – H₃C-(CH₂)₁₃-
• – H₃C-(CH₂)₁₅-
• – H₃C-(CH₂)₇-CH=CH-(CH₂)₇

oder Mischungen aus diesen.In summary, hair treatment compositions according to the invention are preferred in which the radical R in the formulas (VI) and (VII) is selected from

• - H ₃ C- (CH ₂ ) ₇
• H ₃ C- (CH ₂ ) ₉ -
• - H ₃ C- (CH ₂ ) ₁₁ -
• H ₃ C- (CH ₂ ) ₁₃ -
• - H ₃ C- (CH ₂ ) ₁₅ -
• - H ₃ C- (CH ₂ ) ₇ -CH = CH- (CH ₂ ) ₇

or mixtures of these.

Particularly preferred nonionic surfactants are alkyl polyglycosides. Accordingly, hair treatment compositions according to the invention are preferred which contain as nonionic surfactants - based on their weight - 0.1 to 20 wt .-% alkylpolyglycosides of the general formula RO- (Z) _x , where R is alkyl, Z for sugar and x for the number the sugar units stands.

Alkylpolyglycosides (APG) are non-ionic surfactants which are produced entirely from renewable raw materials (sugar components, predominantly glucose, for example from corn starch and fatty alcohol, for example from coconut oil). Alkyl polyglycosides are accessible by acid-catalyzed reaction (Fischer reaction) of sugars, especially glucose (or starch) or butyl glycosides with fatty alcohols.

Complex mixtures of alkyl monoglucoside (alkyl-α-D- and -β-D-glucopyranoside and small amounts of glucofuranoside), alkyldiglucosides (-isomaltosides, maltosides etc.) and Alkyl oligoglucosides (maltotriosides, tetraosides etc.). The average degree of polymerization of commercial products whose alkyl radicals are in the range C8-C16 is 1.2-1.5.

• – im wesentlichen aus C₈- und C₁₀-Alkylgruppen,
• – im wesentlichen aus C₁₂- und C₁₄-Alkylgruppen,
• – im wesentlichen aus C₈- bis C₁₆-Alkylgruppen oder
• – im wesentlichen aus C₁₂- bis C₁₆-Alkylgruppen oder
• – im wesentlichen aus C₁₆ bis C₁₈-Alkylgruppen

besteht.According to the invention, preference is given to using alkylpolyglycosides corresponding to the general formula RO - (Z) _x , where R is alkyl, Z is sugar and x is the number of sugar units. Particular preference is given to those alkylpolyglycosides in which R

• Consisting essentially of C ₈ and C ₁₀ -alkyl groups,
• Essentially of C ₁₂ and C ₁₄ alkyl groups,
• - Essentially from C ₈ - to C ₁₆ alkyl groups or
• - Essentially from C ₁₂ - to C ₁₆ alkyl groups or
• - Substituted from C ₁₆ to C ₁₈ alkyl groups

consists.

As sugar building block Z it is possible to use any desired mono- or oligosaccharides. Usually, sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used. Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.

Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.

The alkylpolyglycosides which can be used according to the invention contain on average from 1.1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1.1 to 1.8.

Other surfactants which can be used particularly advantageously in the compositions according to the invention, especially in admixture with alkylpolyglycosides, are glutamates, asparaginates and sulfoacetates. Here, hair treatment compositions according to the invention are preferred which contain, based on their weight, 0.1 to 20% by weight of fatty acid glutamates (acylglutamates) and / or fatty acid asparaginates (acylasparaginates) and / or alkylsulfoacetates (sulfoacetic acid alkyl esters).

beschreiben, in der R-CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0 und/oder 1, 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alka nolammonium oder Glucammonium steht.Acylglutamate can be defined by the formula

in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alka nolammonium or glucammonium stands.

Surprisingly, it has been found that blends of alkyl glucosides with acyl glutamates have a very good dermatological compatibility and an improved foamability both with regard to the base foam and the foam stability in the presence of water hardness.

Acylglutamates are known anionic surfactants which can be obtained, for example, by Schotten-Baumann acylation of glutamic acid with fatty acids, fatty acid esters or chlorides. Products for sale are available, for example, from Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP.

Typical examples of suitable acylglutamates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C12 / 14 or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particular preference is given to sodium N-cocoyl and sodium N-stearoyl-L-glutamate. The agents according to the invention may contain the alkyl and / or Alkenyl oligoglucosides and the acyl glutamates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.

beschreiben, in der R-CO für einen linearen oder verzweigten Acylrest mit 6 bis 22 Kohlenstoffatomen und 0 und/oder 1, 2 oder 3 Doppelbindungen und X für Wasserstoff, ein Alkali- und/oder Erdalkalimetall, Ammonium, Alkylammonium, Alka nolammonium oder Glucammonium steht.Acylasparaginates can be defined by the formula

in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alka nolammonium or glucammonium stands.

Acylasparaginates are known anionic surfactants which can be obtained, for example, by Schotten-Baumann acylation of aspartic acid with fatty acids, fatty acid esters or chlorides. Products for sale are available, for example, from Hoechst AG, Frankfurt / DE or Ajinomoto Co. Inc., Tokyo / JP.

Typical examples of suitable acylasparaginates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18, carbon atoms, such as, for example, C12 / 14 or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particular preference is given to sodium N-cocoyl and sodium N-stearoyl-L-asparaginate. The agents according to the invention may also contain the alkyl and / or alkenyl oligoglucosides and the acylasparaginates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90 : 10 and especially 80:20 to 50:50.

Sulfoacetates (sulfoacetic acid esters), are usually salts of esters of sulfoacetic acid and can be represented by the general formula ROC (O) -CH ₂ -SO ₂ -OX in which R is a linear or branched alkyl or alkenyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium stands.

Particularly preferred is the use of the sodium salt of sulfoacetic acid with the INCI name: sodium lauryl sulfoacetate): H ₃ C- (CH ₂ ) ₁₁ -O-CO-CH ₂ -SO ₂ -ONa Sodium lauryl sulphoacetate is a white, free-flowing powder which reacts neutrally, with good foaming power, wetting power and dispersibility.

Cationic surfactants of the quaternary ammonium compound type, the esterquats and the amidoamines can be used according to the invention. Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides. The long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as. In cetyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, lauryl dimethyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride and tricetylmethyl ammonium chloride. Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.

• – Alkyltrimethylammoniumchloriden mit vorzugsweise 10 bis 18 Kohlenstoffatomen im Alkylrest und/oder
• – Dialkyldimethylammoniumchloride mit vorzugsweise 10 bis 18 Kohlenstoffatomen im Alkylrest und/oder
• – Trialkylmethylammoniumchloride mit vorzugsweise 10 bis 18 Kohlenstoffatomen im Alkylrest und/oder
• – Cetyltrimethylammoniumchlorid und/oder
• – Stearyltrimethylammoniumchlorid und/oder
• – Distearyldimethylammoniumchlorid und/oder
• – Lauryldimethylammoniumchlorid und/oder
• – Lauryldimethylbenzylammoniumchlorid und/oder
• – Tricetylmethylammoniumchlorid
• – Quaternium-27 und/oder
• – Quaternium-83 und/oder
• – N-Methyl-N(2-hydroxyethyl)-N,N-(ditalgacyloxyethyl)ammonium-methosulfat und/oder
• – N-Methyl-N(2-hydroxyethyl)-N,N-(distearoyloxyethyl)ammonium-methosulfat und/oder
• – N,N-Dimethyl-N,N-distearoyloxyethyl-ammoniumchlorid und/oder
• – N,N-Di-(2-hydroxyethyl)-N,N-(fettsäureesterethyl)-ammoniumchlorid.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as cationic care substance - based on their weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0.2 to 3, 5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) surfactant (s) from the group of quaternary ammonium compounds and / or the esterquats and / or the amidoamines containing preferred cationic (s) Surfactant (s) is / are selected

• - Alkyltrimethylammoniumchloriden having preferably 10 to 18 carbon atoms in the alkyl radical and / or
• - Dialkyldimethylammoniumchloride having preferably 10 to 18 carbon atoms in the alkyl radical and / or
• - Trialkylmethylammoniumchloride preferably having 10 to 18 carbon atoms in the alkyl radical and / or
• Cetyltrimethylammonium chloride and / or
• Stearyltrimethylammonium chloride and / or
• Distearyldimethylammonium chloride and / or
• - Lauryldimethylammonium chloride and / or
• - Lauryldimethylbenzylammoniumchlorid and / or
• - tricetylmethylammonium chloride
• - Quaternium-27 and / or
• - Quaternium-83 and / or
• - N-methyl-N (2-hydroxyethyl) -N, N- (ditalgacyloxyethyl) ammonium methosulfate and / or
• - N-methyl-N (2-hydroxyethyl) -N, N- (distearoyloxyethyl) ammonium methosulfate and / or
• - N, N-dimethyl-N, N-distearoyloxyethyl ammonium chloride and / or
• - N, N-di (2-hydroxyethyl) -N, N- (fatty acid ethyl) ammonium chloride.

The care effects of the compositions according to the invention can be further enhanced by using certain care substances. Preferably, these are selected from certain groups of known care substances, since these care substances harmonize perfectly with the formulation and the care effect with the combination used according to the invention against dandruff.

• i. L-Carnitin und/oder seiner Salze;
• ii. Taurin und/oder seiner Salze;
• iii. Niacinamid;
• iv. Ubichinon
• v. Ectoin;

According to preferred hair treatment compositions are characterized in that they additionally care substance (s) - based on their weight - in amounts of 0.001 to 10 wt .-%, preferably 0.005 to 7.5 wt .-%, particularly preferably 0.01 to 5 wt % and in particular 0.05 to 2.5 wt .-%, with preferred care substance (s) are selected from the group

• i. L-carnitine and / or its salts;
• ii. Taurine and / or its salts;
• iii. niacinamide;
• iv. ubiquinone
• v. Ectoin;

L-carnitine (IUPAC name (R) - (3-carboxy-2-hydroxypropyl) -N, N, N-trimethylammonium hydroxide) is a naturally occurring, vitamin-like substance. It plays an essential role in the energy metabolism of human, animal and plant cells. L-carnitine can be obtained in various ways on an industrial scale. For example, a, the body's own biosynthesis imitating, biotechnological process: In large fermentation tanks while the precursor of L-carnitine (γ-butyrobetaine) using Gram-negative bacteria (rhizobia) is converted into L-carnitine.

As betaine, L-carnitine can form addition compounds and double salts. L-carnitine derivatives which are preferred according to the invention are selected in particular from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and particularly preferably L-carnitine tartrate. The L-carnitine compounds mentioned are available, for example, from Lonza GmbH (Wuppertal, Germany).

Preferred hair treatment compositions according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.005 to 7.5% by weight, particularly preferably from 0.01 to 5% by weight and in particular 0.05 contain up to 2.5 wt .-% L-carnitine or L-carnitine derivatives, with preferred L-carnitine derivatives are selected from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.

Another, more preferably usable care substance which has activating properties is taurine. According to the invention preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).

Another preferred group of care agents in the compositions according to the invention are vitamins, provitamins or vitamin precursors. These are described below:
The group of substances called vitamin A includes retinol (vitamin A ₁ ) and 3,4-didehydroretinol (vitamin A ₂ ). The β-carotene is the provitamin of retinol. As vitamin A component according to the invention, for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as palmitate and acetate. The agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.

• – Vitamin B₁ (Thiamin)
• – Vitamin B₂ (Riboflavin)
• – Vitamin B₃. Unter dieser Bezeichnung werden häufig die Verbindungen Nicotinsäure und Nicotinsäureamid (Niacinamid) geführt. Erfindungsgemäß bevorzugt ist das Nicotinsäureamid, das in den erfindungsgemäß verwendeten Mitteln bevorzugt in Mengen von 0,05 bis 1 Gew.-%, bezogen auf das gesamte Mittel, enthalten ist.
• – Vitamin B₅ (Pantothensäure, Panthenol und Pantolacton). Im Rahmen dieser Gruppe wird bevorzugt das Panthenol und/oder Pantolacton eingesetzt (siehe weiter unten). Erfindungsgemäß einsetzbare Derivate des Panthenols sind insbesondere die Ester und Ether des Panthenols sowie kationisch derivatisierte Panthenole. Einzelne Vertreter sind beispielsweise das Panthenoltriacetat, der Panthenolmonoethylether und dessen Monoacetat sowie die in der WO 92/13829 offenbarten kationischen Panthenolderivate. Die genannten Verbindungen des Vitamin B₅-Typs sind in den erfindungsgemäßen Mitteln bevorzugt in Mengen von 0,05–10 Gew.-%, bezogen auf das gesamte Mittel, enthalten. Mengen von 0,1–5 Gew.-% sind besonders bevorzugt.
• – Vitamin B₆ (Pyridoxin sowie Pyridoxamin und Pyridoxal).

The vitamin B group or the vitamin B complex include, among others

• - Vitamin B ₁ (thiamine)
• - Vitamin B ₂ (riboflavin)
• - Vitamin B ₃ . Under this name, the compounds nicotinic acid and nicotinamide (niacinamide) are often performed. Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
• - Vitamin B ₅ (pantothenic acid, panthenol and pantolactone). Panthenol and / or pantolactone are preferably used in the context of this group (see below). Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are for example the Panthenoltriacetat, the Panthenolmonoethylether and its monoacetate as well as in the WO 92/13829 disclosed cationic panthenol derivatives. The said compounds of the vitamin B ₅ type are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
• - Vitamin B ₆ (pyridoxine and pyridoxamine and pyridoxal).

Vitamin C (ascorbic acid). Vitamin C is used in the agents according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.

Vitamin E (tocopherols, especially α-tocopherol). Tocopherol and its derivatives, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.

Vitamin F. The term "vitamin F" is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.

Vitamin H. Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] -imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile become established. Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.

In summary, hair-treatment compositions according to the invention are preferred which, based on their weight, are 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.25 to 3.5% by weight, more preferably Contain 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors, preferably the groups A, B, C, E, F and H. 2,4,4-dihydroxy-N- (3-hydroxypropyl) -3,3-dimethylbutyramide, provitamin B ₅ ) and / or pantothenic acid (vitamin B ₃ , vitamin B ₅ ) and / or niacin , Niacinamide or nicotinamide (vitamin B ₃ ) and / or L-ascorbic acid (vitamin C) and / or thiamine (vitamin B ₁ ) and / or riboflavin (vitamin B ₂ , vitamin G) and / or biotin (vitamin B ₇ , Vitamin H) and / or folic acid (vitamin B ₉ , vitamin B _c or vitamin M) and / or vitamin B ₆ and / or vitamin B ₁₂ .

enthalten in der
X, Y, Z stehen unabhängig voneinander für -O- oder -NH- oder NR⁴- oder eine chemische Bindung
R¹, R², R³ stehen unabhängig voneinander für ein Wasserstoffatom oder eine gegebenenfalls substituierte Arylgruppe oder eine gegebenenfalls substituierte (C₁-C₆)-Alkylgruppe oder eine Hydroxyalkylgruppe oder eine Polyhydroxyalkylgruppe oder eine gegebenenfalls substituierte (C₁-C₆)-Alkylengruppe, oder einen (C₁-C₆)-Acylrest, wobei bevorzugte Reste unabhängig voneinander ausgewählt sind aus -H, -CH₃, -CH₂CH₃, -(CH₂)₂CH₂, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃
R⁴ steht für -CH₃, -CH₂CH₃, -(CH₂)₂CH₂, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃
n steht für Werte von 1 bis 20, vorzugsweise von 2 bis 15 und insbesondere für 5, 6, 7, 8, 9, 10.It has been shown that certain quinones have a special suitability as a care substance. As a further care substance, the compositions according to the invention can therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)

contained in the
X, Y, Z are independently -O- or -NH- or NR ⁴ - or a chemical bond
R ¹ , R ² , R ³ independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C ₁ -C ₆ ) -alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (C ₁ -C ₆ ) - Alkylene group, or a (C ₁ -C ₆ ) -acyl radical, preferred radicals being selected independently of one another from -H, -CH ₃ , -CH ₂ CH ₃ , - (CH ₂ ) ₂ CH ₂ , -CH (CH ₃ ) ₂ , - (CH ₂ ) ₃ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -CH ₂ CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃
R ⁴ is -CH ₃ , -CH ₂ CH ₃ , - (CH ₂ ) ₂ CH ₂ , -CH (CH ₃ ) ₂ , - (CH ₂ ) ₃ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -CH ₂ CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃
n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.

in denen
R¹, R², R³ stehen jeweils unabhängig voneinander für -H, -CH₃, -CH₂CH₃, -(CH₂)₂CH₂, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃
R⁴ steht für -CH₃, oder -CH₂CH₃, oder -(CH₂)₂CH₂, oder -CH(CH₃)₂
n steht für Werte von 1 bis 20, vorzugsweise von 2 bis 15 und insbesondere für 5, 6, 7, 8, 9, 10.Preferred compounds of the formula (Ubi) according to the invention are, for example

in which
R ¹ , R ² , R ³ are each independently -H, -CH ₃ , -CH ₂ CH ₃ , - (CH ₂ ) ₂ CH ₂ , -CH (CH ₃ ) ₂ , - (CH ₂ ) ₃ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -CH ₂ CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃
R ⁴ is -CH ₃ , or -CH ₂ CH ₃ , or - (CH ₂ ) ₂ CH ₂ , or -CH (CH ₃ ) ₂
n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.

in der n für die Werte = 6, 7, 8, 9 oder 10, besonders bevorzugt für 10 (Coenzym Q10) steht.Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0.1 wt .-% containing at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, preferred agents containing a ubiquinone of the formula (Ubi)

in which n stands for the values = 6, 7, 8, 9 or 10, particularly preferably 10 (coenzyme Q10).

in der n für Werte von 1 bis 20, vorzugsweise von 2 bis 15 und insbesondere für 5, 6, 7, 8, 9, 10 steht, wobei besonders bevorzugt Mittel Plastochinon PQ-9 der Formel

enthalten. As an alternative to the particularly preferred ubiquinones or in addition to them, the agents according to the invention may also contain plastoquinones. Here, preferred agents according to the invention are characterized in that they are 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-b)

in which n stands for values of 1 to 20, preferably of 2 to 15 and in particular for 5, 6, 7, 8, 9, 10, whereby particularly preferred means Plastochinon PQ-9 of the formula

contain.

As a further care enhancer, the agents according to the invention may contain ectoin. Ectoine ((4S) -2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid) is a natural product belonging to the group of compatible solutes. The highly water-binding low molecular weight organic compound occurs in halophilic bacteria and allows these extremophilic organisms to survive under stress conditions. Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0 , 1 to 1% by weight of (S) -2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (ectoine) and the physiologically tolerated salts of this compound and / or (S, S) -5- Hydroxy-2-methyl-1,4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (hydroxyectoine) and the physiologically acceptable salts of this compound.

To improve the elasticity and strengthen the internal structure of the hair treated with the agents according to the invention, the compositions according to the invention may contain purine and / or purine derivatives as a care substance. In particular, the combination of purine and / or purine derivatives with ubiquinones and / or plastoquinones as a care substance means that the hairs treated with corresponding agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.

Purine (7H-imidazo [4,5-d] pyrimidine) does not occur freely in nature, but forms the main body of purines. Purines, in turn, are a group of important compounds naturally involved in human, animal, plant and microbial metabolic processes which are different from the parent by substitution with OH, NH ₂ , SH at the 2-, 6-, and 8-positions and / or with CH ₃ in 1-, 3-, 7-position derived. Purine can be prepared, for example, from aminoacetonitrile and formamide. Purines and purine derivatives are often isolated from natural products, but are also synthetically accessible in many ways.

Preferred agents according to the invention contain purine and / or purine derivatives in narrower quantitative ranges. Here, preferred cosmetic compositions according to the invention are characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, especially preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0.1 wt .-% purine (s) and / or purine derivative (s).

in der die Reste R¹, R² und R³ unabhängig voneinander ausgewählt sind aus -H, -OH, NH₂, -SH und die Reste R⁴, R⁵ und R⁶ unabhängig voneinander ausgewählt sind aus -H, -CH₃ und -CH₂-CH₃, wobei folgende Verbindungen bevorzugt sind:

• – Purin (R¹ = R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – Adenin (R¹ = NH₂, R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – Guanin (R¹ = OH, R² = NH₂, R³ = R⁴ = R⁵ = R⁶ = H)
• – Harnsäure (R¹ = R² = R³ = OH, R⁴ = R⁵ = R⁶ = H)
• – Hypoxanthin (R¹ = OH, R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – 6-Purinthiol (R¹ = SH, R² = R³ = R⁴ = R⁵ = R⁶ = H)
• – 6-Thioguanin (R¹ = SH, R² = NH₂, R³ = R⁴ = R⁵ = R⁶ = H)
• – Xanthin (R¹ = R² = OH, R³ = R⁴ = R⁵ = R⁶ = H)
• – Coffein (R¹ = R² = OH, R³ = H, R⁴ = R⁵ = R⁶ = CH₃)
• – Theobromin (R¹ = R² = OH, R³ = R⁴ = H, R⁵ = R⁶ = CH₃)
• – Theophyllin (R¹ = R² = OH, R³ = H, R⁴ = CH₃, R⁵ = CH₃, R⁶ = H).

Among purine, the purines and the purine derivatives, some representatives are particularly preferred according to the invention. Hair treatment compositions which are preferred according to the invention are characterized in that they contain as care substance - based on their weight - from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s), preferred agents containing purine and / or purine derivative (s) of formula (Pur-I)

in which the radicals R ¹ , R ² and R ^{3 are} independently selected from -H, -OH, NH ₂ , -SH and the radicals R ⁴ , R ⁵ and R ^{6 are} independently selected from -H, -CH ₃ and -CH ₂ -CH ₃ , where the following compounds are preferred:

• Purine (R ¹ = R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Adenine (R ¹ = NH ₂ , R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Guanine (R ¹ = OH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Uric acid (R ¹ = R ² = R ³ = OH, R ⁴ = R ⁵ = R ⁶ = H)
• Hypoxanthine (R ¹ = OH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• 6-purethiol (R ¹ = SH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• 6-thioguanine (R ¹ = SH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Xanthine (R ¹ = R ² = OH, R ³ = R ⁴ = R ⁵ = R ⁶ = H)
• Caffeine (R ¹ = R ² = OH, R ³ = H, R ⁴ = R ⁵ = R ⁶ = CH ₃ )
• - Theobromine (R ¹ = R ² = OH, R ³ = R ⁴ = H, R ⁵ = R ⁶ = CH ₃ )
• Theophylline (R ¹ = R ² = OH, R ³ = H, R ⁴ = CH ₃ , R ⁵ = CH ₃ , R ⁶ = H).

It is also advantageous to use purine or purine derivatives and biochinones in a certain ratio to each other. Here, agents according to the invention are preferred in which the weight ratio of purine (derivative (s)) and biochinone (s) 10: 1 to 1: 100, preferably 5: 1 to 1:50, particularly preferably 2: 1 to 1:20 and especially 1: 1 to 1:10.

As already mentioned, caffeine is a particularly preferred purine derivative, and coenzyme Q10 is a particularly preferred biochinone. Particularly preferred agents according to the invention are therefore characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular 0.01 to 0.1 wt .-% caffeine and 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% coenzyme Q10 included.

As a conditioner, the compositions of the invention may also contain flavonoids. The flavonoids are a group of water-soluble plant dyes and play an important role in the metabolism of many plants. They belong together with the phenolic acids to the polyphenols. There are well over 6500 different flavonoids known, which can be divided into flavonols, flavones, flavanones, isoflavonoids and anthocyanins.

According to the invention flavonoids from all six groups can be used, with certain representatives from the individual groups are preferred as a care substance because of their particularly intense action. Preferred flavonols are quercetin, rutin, kaempferol, myricetin, isorhamnetin, preferred flavanols are catechin, gallocatechin, epicatechin, epigallocatechin gallate, theaflavin, thearubigin, preferred flavones are luteolin, apigenin, morin, preferred flavanones are hesperetin, naringenin, eriodictyol, preferred isoflavonoids are genistein , Daidzein, and preferred anthocyanidins (anthocyanins) are cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin.

According to the invention particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0.1% by weight of flavonoids, in particular flavonols, more preferably 3,3 ', 4', 5,7-pentahydroxyflavone (quercetin) and / or 3,3 ', 4', 5,7-pentahydroxyflavone -3-O-rutinoside (rutin), included.

enthalten. Preference is also the use of bisabolol and / or bisabololoxides as a care substance in the inventive compositions. Here, hair treatment compositions according to the invention are preferred which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1.5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol

contain.

Creatine is also suitable as a care substance according to the invention. Creatine (3-methylguanidinoacetic acid) is an organic acid found in vertebrates and the like. a. contributes to supplying the muscles with energy. Creatine is synthesized in the kidney, liver and pancreas. It is formally derived from the amino acids glycine and arginine and is 95% present in skeletal muscle. Particularly preferred hair treatment compositions according to the invention contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0.1 to 7.5 wt .-% and in particular 0.5 to 5 wt .-% N-methyl-guanidino-acetic acid (creatine).

The compositions according to the invention may contain, in addition to the ingredients mentioned above and optional further ingredients, other substances which prevent, alleviate or cure hair loss. In particular, a content of hair root stabilizing agents is advantageous. These substances are described below:
Propecia (Finasteride) is currently the only preparation that is approved worldwide and has been proven in many studies to be effective and tolerable. Propecia causes less DHT to form from testosterone.

Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. For the treatment of hair loss, it may only be used for external application. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil. The effectiveness increases with the dosage, in hair waters Minoxidil is only up to 5% share soluble. In many countries, hair tonic with up to 2% minoxidil content is available without prescription.

To combat the hormonal influences on the hair follicles spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application. Spironolactone acts as an androgen receptor blocker, ie. the binding of DHT to the hair follicles is prevented.

In summary, hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.

In addition to the care agents, the agents according to the invention may contain further care substances. Their presence is not absolutely necessary for achieving the effects according to the invention, but further effects, such as a pleasant touch or a pleasant application feel, can result from the use of these care substances.

• – Monosachhariden, insbesondere
• – D-Ribose und/oder
• – D-Xylose und/oder
• – L-Arabinose und/oder
• – D-Glucose und/oder
• – D-Mannose und/oder
• – D-Galactose und/oder
• – D-Fructose und/oder
• – Sorbose und/oder
• – L-Fucose und/oder
• – L-Rhamnose
• – Disacchariden, insbesondere
• – Saccharose und/oder
• – Maltose und/oder
• – Lactose und/oder
• – Trehalose und/oder
• – Cellobiose und/oder
• – Gentiobiose und/oder
• – Isomaltose.

As a further component, the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides. Here are preferred hair treatment compositions according to the invention characterized in that they are used as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt. -%, more preferably 0.5 to 3.5 wt .-% and in particular 0.75 to 2.5 wt .-% carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides containing preferred carbohydrates are selected out

• - Monosaccharides, in particular
• D-ribose and / or
• - D-xylose and / or
• - L-arabinose and / or
• D-glucose and / or
• - D-mannose and / or
• D-galactose and / or
• - D-fructose and / or
• - sorbose and / or
• - L-fucose and / or
• - L-rhamnose
• - Disaccharides, in particular
• - sucrose and / or
• - maltose and / or
• - lactose and / or
• - Trehalose and / or
• Cellobiose and / or
• - Gentiobiose and / or
• - Isomaltose.

• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Glucosemonohydrat,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Saccharose,
• – 0,005 bis 0,015 Gew.-% Coffein und 0,75 bis 1,5 Gew.-% Fructose.

Particularly preferred agents according to the invention contain based on their weight

• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose,
• 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose.

A particularly preferred group of ingredients are the silicones.

• (i) Polyalkylsiloxanen, Polyarylsiloxanen, Polyalkylarylsiloxanen, die flüchtig oder nicht flüchtig, geradkettig, verzweigt oder cyclisch, vernetzt oder nicht vernetzt sind; (ii) Polysiloxanen, die in ihrer allgemeinen Struktur eine oder mehrere organofunktionelle Gruppen enthalten, die ausgewählt sind unter: a) substituierten oder unsubstituierten aminierten Gruppen; b) (per)fluorierten Gruppen; c) Thiolgruppen; d) Carboxylatgruppen; e) hydroxylierten Gruppen; f) alkoxylierten Gruppen; g) Acyloxyalkylgruppen; h) amphoteren Gruppen; i) Bisulfitgruppen; j) Hydroxyacylaminogruppen; k) Carboxygruppen; l) Sulfonsäuregruppen; und m) Sulfat- oder Thiosulfatgruppen;
• (iii) linearen Polysiloxan(A)-Polyoxyalkylen(B)-Blockcopoylmeren vom Typ (A-B)_n mit n > 3;
• (iv) gepfropften Siliconpolymeren mit nicht siliconhaltigem, organischen Grundgerüst, die aus einer organischen Hauptkette bestehen, welche aus organischen Monomeren gebildet wird, die kein Silicon enthalten, auf die in der Kette sowie gegebenenfalls an mindestens einem Kettenende mindestens ein Polysiloxanmakromer gepfropft wurde;
• (v) gepfropften Siliconpolymeren mit Polysiloxan-Grundgerüst, auf das nicht siliconhaltige, organische Monomere gepfropft wurden, die eine Polysiloxan-Hauptkette aufweisen, auf die in der Kette sowie gegebenenfalls an mindestens einem ihrer Enden mindestens ein organisches Makromer gepfropft wurde, das kein Silicon enthält;

oder deren Gemischen.Preferred agents according to the invention are characterized in that they comprise at least one silicone, preferably a silicone, selected from:

• (i) polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes which are volatile or nonvolatile, straight chain, branched or cyclic, crosslinked or uncrosslinked; (ii) polysiloxanes containing in their general structure one or more organofunctional groups selected from: a) substituted or unsubstituted aminated groups; b) (per) fluorinated groups; c) thiol groups; d) carboxylate groups; e) hydroxylated groups; f) alkoxylated groups; g) acyloxyalkyl groups; h) amphoteric groups; i) bisulfite groups; j) hydroxyacylamino groups; k) carboxy groups; l) sulfonic acid groups; and m) sulfate or thiosulfate groups;
• (iii) linear polysiloxane (A) polyoxyalkylene (B) block copolymers of the (AB) _{n type} with n>3;
• (iv) grafted silicone polymers having a non-silicone organic backbone consisting of an organic backbone formed from organic monomers containing no silicone grafted with at least one polysiloxane macromer in the chain and optionally at least one chain end;
• (v) grafted polysiloxane backbone silicone polymers having grafted thereto non-silicone organic monomers having a polysiloxane backbone to which at least one organic macromer not containing silicone has been grafted in the chain, and optionally at least at one of its ends ;

or their mixtures.

Particularly preferred compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.

Preferred silicones are described below.

Particularly preferred agents according to the invention are characterized in that they contain at least one silicone of the formula Si-I (CH ₃ ) ₃ Si [OS (CH ₃ ) ₂ ] _x -O-Si (CH ₃ ) ₃ (Si-I), in which x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.

These silicones are called DIMETHICONE according to the INCI nomenclature. In the context of the present invention, as the silicone of the formula Si-1, the compounds are preferably:
(CH ₃ ) ₃ Si-O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si-O- (CH ₃ ) ₂ Si-O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₂ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₃ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₄ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₅ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₆ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₇ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] 8-O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₉ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₀ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₁ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₂ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₃ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₄ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₅ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₆ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₇ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₈ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₉ -O-Si (CH ₃ ) ₃
(CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₂₀ -O-Si (CH ₃ ) ₃ , where (CH ₃ ) ₃ Si - O-Si (CH ₃ ) ₃ , (OH ₃ ) ₃ Si-O- (CH ₃ ) ₂ Si-O-Si (CH ₃ ) ₃ and / or (CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₂ -O-Si (CH ₃ ) _{3 are} particularly preferred.

Of course, mixtures of o. G. Silicones may be included in the compositions of the invention.

Preferred silicones which can be used according to the invention have viscosities of from 0.2 to 2 mm ² s ^-1 at 20 ° C., silicones having viscosities of from 0.5 to 1 mm ² s ^{-1 being} particularly preferred.

Particularly preferred agents according to the invention contain one or more amino-functional silicones. Such silicones may, for. B. by the formula M (R _a Q _b SiO _{(4-ab) / 2) x} (R _c SiO _{(4-c) / 2) y} M wherein R in the above formula is a hydrocarbon or a hydrocarbon group of 1 to about 6 carbon atoms, Q is a polar group of the general formula -R ¹ HZ wherein R ^{1 is} a divalent linking group attached to hydrogen and the group Z is an organic, amino-functional radical containing at least one amino-functional group, carbon and hydrogen atoms, carbon, hydrogen and oxygen atoms or carbon, hydrogen and nitrogen atoms; "A" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 1 to about 3, "a" + "b" is less than or equal to 3, and "c" is a number in the range from about 1 to about 3, and x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25, and y is a number ranging from about 20 to about 10,000 , preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000, and M is a suitable silicone end group as known in the art, preferably trimethylsiloxy. Non-limiting examples of the groups represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals, such as cyclobutyl, Cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, 4-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur-containing radicals such as mercaptoethyl, mercaptopropyl, mercaptohexyl, mercaptophenyl and the like; preferably R is an alkyl radical containing from 1 to about 6 carbon atoms, and most preferably R is methyl. Examples of R ¹ include methylene, ethylene, propylene, hexamethylene, decamethylene, -CH ₂ CH (CH ₃ ) CH ₂ -, phenylene, naphthylene, -CH ₂ CH ₂ SCH ₂ CH ₂ -, -CH ₂ CH ₂ OCH ₂ - , -OCH ₂ CH ₂ -, -OCH ₂ CH ₂ CH ₂ -, -CH ₂ CH (CH ₃ ) C (O) OCH ₂ -, - (CH ₂ ) ₃ CC (O) OCH ₂ CH ₂ -, C ₆ H ₄ C ₆ H ₄ -, -C ₆ H ₄ CH ₂ C ₆ H ₄ -; and - (CH ₂ ) ₃ C (O) SCH ₂ CH ₂ -.

Z is an organic, amino-functional radical containing at least one functional amino group. A possible formula for Z is NH (CH ₂ ) _z NH ₂ , wherein z is 1 or more. Another possible formula for Z is -NH (CH ₂ ) _z (CH ₂ ) _zz NH, wherein both z and zz are independently 1 or more, which structure includes diamino ring structures, such as piperazinyl. Z is most preferably a -NHCH ₂ CH ₂ NH ₂ radical. Another possible formula for Z is -N (OH ₂ ) _z (OH ₂ ) NX ₂ or -NX ₂ , wherein each X of X _{2 is} independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz 0 is.

Q is most preferably a polar, amine functional group of the formula -CH ₂ CH ₂ CH ₂ NHCH ₂ CH ₂ NH ₂ . In the formulas, "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 2 to about 3, "a" + "b" is less than or equal to 3, and "c "Is a number in the range of about 1 to about 3. The molar ratio of the R _a Q _b SiO _{(4-ab) / 2} units to the R _c SiO _{(4-c) / 2} units is in the range of about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1:15 to about 1:20. When one or more silicones of the above formula are used, the various variable substituents in the above formula may be different for the various silicone components present in the silicone blend.

• – G ist -H, eine Phenylgruppe, -OH, -O-CH₃, -CH₃, -O-CH₂CH₃, -CH₂CH₃, -O-OH₂OH₂CH₃, -CH₂CH₂CH₃, -O-CH(CH₃)₂, -CH(CH₃)₂, -O-CH₂CH₂CH₂CH₃, -OH₂OH₂OH₂OH₃, -O-CH₂CH(CH₃)₂, -CH₂CH(CH₃)₂, -O-CH(CH₃)CH₂CH₃, -CH(CH₃)CH₂CH₃, -O-C(CH₃)₃, -C(CH₃)₃;
• – a steht für eine Zahl zwischen 0 und 3, insbesondere 0;
• – b steht für eine Zahl zwischen 0 und 1, insbesondere 1,
• – m und n sind Zahlen, deren Summe (m + n) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei n vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt,
• – R' ist ein monovalenter Rest ausgewählt aus • -Q-N(R'')-CH₂-CH₂-N(R'')₂ • -Q-N(R'')₂ • -Q-N⁺(R'')₃A^– • -Q-N⁺H(R'')₂A^– • -Q-N⁺H₂(R'')A^– • -Q-N(R'')-CH₂-CH₂-N⁺R''H₂A^–, wobei jedes Q für eine chemische Bindung, -CH₂-, -CH₂-CH₂-, -CH₂CH₂CH₂-, -C(CH₃)₂-, -CH₂CH₂CH₂CH₂-, -CH₂C(CH₃)₂-, -CH(CH₃)CH₂CH₂- steht, R'' für gleiche oder verschiedene Reste aus der Gruppe -H, -Phenyl, -Benzyl, -CH₂-CH(CH₃)Ph, der C_1-20-Alkylreste, vorzugsweise -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH(CH₃)₂, -CH₂CH₂CH₂H₃, -CH₂CH(CH₃)₂, -CH(CH₃)CH₂CH₃, -C(CH₃)₃, steht und A ein Anion repräsentiert, welches vorzugsweise ausgewählt ist aus Chlorid, Bromid, Iodid oder Methosulfat.

Preferred agents according to the invention are characterized in that they contain an amino-functional silicone of the formula (Si-II) R _'a G _3-a -Si (OSiG _{2) n} - (OSiG _b R' _{2-b) m} -O-SiG _3-a -R _'a (Si-II), contain, in which means:

• G is -H, a phenyl group, -OH, -O-CH ₃ , -CH ₃ , -O-CH ₂ CH ₃ , -CH ₂ CH ₃ , -O-OH ₂ OH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -O-CH (CH ₃ ) ₂ , -CH (CH ₃ ) ₂ , -O-CH ₂ CH ₂ CH ₂ CH ₃ , -OH ₂ OH ₂ OH ₂ OH ₃ , -O-CH ₂ CH (CH ₃ ) ₂ , -CH ₂ CH (CH ₃ ) ₂ , -O-CH (CH ₃ ) CH ₂ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -OC (CH ₃ ) ₃ , -C (CH ₃ ) ₃ ;
• A is a number between 0 and 3, in particular 0;
• B is a number between 0 and 1, in particular 1,
• M and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n is preferably values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10,
• R 'is a monovalent radical selected from • -QN (R'') - CH ₂ -CH ₂ -N (R'') ₂ • -QN (R'') ₂ • -QN ⁺ (R'') ₃ A ^- • QN ⁺ H (R '') ₂ A ^- • QN ⁺ _H2 (R '') A ^- • -QN (R '') - CH ₂ -CH ₂ -N ⁺ R''H ₂ A ^- , where each Q is a chemical bond, -CH ₂ -, -CH ₂ -CH ₂ -, -CH ₂ CH ₂ CH ₂ -, -C (CH ₃ ) ₂ -, -CH ₂ CH ₂ CH ₂ CH ₂ -, -CH ₂ C (CH ₃ ) ₂ -, -CH (CH ₃ ) CH ₂ CH ₂ -, R '' is identical or different radicals from the group -H, -phenyl, -benzyl, -CH ₂ -CH (CH ₃ ) Ph, the C _1-20 alkyl radicals, preferably -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH ₂ CH ₂ H ₃ , -CH ₂ CH (CH ₃ ) ₂ , -CH (CH ₃ ) CH ₂ CH ₃ , -C (CH ₃ ) ₃ , and A represents an anion, which is preferably selected from chloride, bromide, iodide or methosulfate.

enthalten, worin m und n Zahlen sind, deren Summe (m + n) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei n vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt.Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)

in which m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.

These silicones are referred to as trimethylsilylamodimethicones according to the INCI declaration.

enthalten, worin R für -OH, -O-CH₃ oder eine -CH₃-Gruppe steht und m, n1 und n2 Zahlen sind, deren Summe (m + n1 + n2) zwischen 1 und 2000, vorzugsweise zwischen 50 und 150 beträgt, wobei die Summe (n1 + n2) vorzugsweise Werte von 0 bis 1999 und insbesondere von 49 bis 149 und m vorzugsweise Werte von 1 bis 2000, insbesondere von 1 bis 10 annimmt.Also particularly preferred are agents according to the invention which are an amino-functional silicone of the formula (Si-IIb)

in which R is -OH, -O-CH ₃ or a -CH ₃ group and m, n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.

These silicones are referred to as amodimethicones according to the INCI declaration.

Regardless of which amino-functional silicones are used, agents according to the invention which contain an amino-functional silicone whose amine number is above 0.25 meq / g, preferably above 0.3 meq / g and in particular above 0.4 meq / g, are preferred , The amine number stands for the milliequivalents of amine per gram of the amino-functional silicone. It can be determined by titration and also expressed in mg KOH / g.

Agents preferred according to the invention are characterized in that they contain, based on their weight, 0.01 to 10 wt .-%, preferably 0.1 to 8 wt .-%, particularly preferably 0.25 to 7.5 wt .-% and in particular from 0.5 to 5% by weight of amino-functional silicone (s).

enthalten, in der x für eine Zahl von 3 bis 200, vorzugsweise von 3 bis 10, weiter bevorzugt von 30 bis 7 und insbesondere 3, 4, 5 oder 6, steht.The INCI CYCLOMETHICONE designated cyclic dimethicones are inventively used with preference. Here, agents according to the invention are preferred which contain at least one silicone of the formula Si-III

in which x is a number from 3 to 200, preferably from 3 to 10, more preferably from 30 to 7 and in particular 3, 4, 5 or 6.

The silicones described above have a backbone composed of -Si-O-Si units. Of course, these Si-O-Si units may also be interrupted by carbon chains. Appropriate molecules are accessible by chain extension reactions and are preferably used in the form of silicone-in-water emulsions.

Agents which are likewise preferred according to the invention are characterized in that they contain at least one silicone of the formula Si-IV R _{3 is} -Si- [O-SiR ₂ ] _x - (CH ₂ ) _n - [O-SiR ₂ ] yO-SiR ₃ (Si-IV), in which R is identical or different radicals from the group -H, -phenyl, -benzyl, -CH ₂ -CH (CH ₃ ) Ph, the C _1-20 -alkyl radicals, preferably -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH ₂ CH ₂ H ₃ , -CH ₂ CH (CH ₃ ) ₂ , -CH (CH ₃ ) CH ₂ CH ₃ , - C (CH ₃ ) ₃ , x and y are a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and especially 0, 1, 2, 3, 4, 5 or 6, stand and n is a number from 0 to 10, preferably from 1 to 8 and in particular from 2, 3, 4, 5, 6.

The silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone.

For aesthetic reasons, "clear" products are often preferred by consumers. Hair treatment compositions which are preferred according to the invention are therefore characterized in that they are transparent or translucent.

In the context of the present invention, transparent or translucent is understood as meaning a composition which has an NTU value of less than 100. The Nephelometric Turbidity Unit (NTU) value is a unit used in water treatment for turbidity measurements in liquids. It is the unit of turbidity measured with a calibrated nephelometer.

Furthermore, in a preferred embodiment of the invention, an agent according to the invention may also contain UV filters (I). The UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC (<280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.

The UV filters used according to the invention can be selected, for example, from substituted benzophenones, p-aminobenzoic acid esters, diphenylacrylic acid esters, cinnamic acid esters, salicylic acid esters, benzimidazoles and o-aminobenzoic acid esters.

Examples of UV filters which can be used according to the invention are 4-aminobenzoic acid, N, N, N-trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline-methylsulfate, 3,3,5-trimethyl-cyclohexylsalicylate (homosalates), 2-hydroxy-4-methoxy-benzophenone (benzophenone-3; Uvinul ^® M 40, Uvasorb MET ^{®, ®} Neo Heliopan BB, Eusolex ^® 4360), 2-phenylbenzimidazole-5-sulfonic acid and potassium, sodium and triethanolamine salts ( Phenylbenzimidazole Sulfonic Acid; Parsol ^® HS; Neo Heliopan Hydro ^®), 3,3 '- (1,4-phenylenedimethylene) -bis (7,7-dimethyl-2-oxo-bicyclo [2.2.1] hept-1- yl-methane sulfonic acid) and salts thereof, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) Methoxydibenzoylmethane -propane-1,3-dione (butyl; Parsol ^® 1789 Eusolex ^® 9020), α - (2-oxoborn-3-ylidene) toluene-4-sulfonic acid and salts thereof, ethoxylated 4-aminobenzoic acid ethyl ester (PEG-25 PABA; Uvinul ^® P 25), 4-dimethylaminobenzoic acid 2-ethylhexyl (octyl dimethyl PABA; Uvasorb ^® DMO, Escalol ^® 507, Eusolex ^® 6007), salicylic acid-2-ethylhexy ester (octyl salicylate; Escalol ^® 587, Neo Heliopan ^® OS, Uvinul ^® O18), 4-methoxycinnamic acid isopentyl (isoamyl p-methoxycinnamate; Neo Heliopan ^® E 1000), 4-methoxycinnamic acid 2-ethylhexyl ester (Octyl Methoxycinnamate; Parsol ^® MCX, Escalol ^® 557, Neo Heliopan AV ^®), 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt (Benzophenone-4; Uvinul ^® MS 40; Uvasorb S 5 ^®), 3- (4'-methylbenzylidene) -D, L-camphor (4-methylbenzylidene camphor; Parsol ^® 5000, Eusolex ^® 6300), 3-benzylidene camphor (3-benzylidene camphor), 4-isopropylbenzyl, 2,4,6-trianilino- (p-carbo-2'- ethylhexyl-1'-oxi) -1,3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of N - {(2 and 4) - [2-oxoborn-3-ylidenemethyl] benzyl } -acrylamids, 2,4-dihydroxy (benzophenone-1; Uvasorb ^® 20 H, Uvinul ^® 400), 1,1'-Diphenylacrylonitrilsäure-2-ethylhexyl ester (Octocrylene; Eusolex ^® OCR, Neo Heliopan ^® Type 303, Uvinul ^® N 539 SG), o-aminobenzoic acid menthyl ester (Menthyl Anthranilate; Neo He liopan ^® MA), 2,2 ', 4,4'-tetrahydroxy benzophenone (benzophenone-2; Uvinul ^® D-50), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone (Benzophenone-6), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone-5-sodium sulfonate, and 2-cyano-3, 3-diphenylacrylate 2'-ethylhexyl acrylate. Preference is given to 4-aminobenzoic acid, N, N, N-trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline methylsulfate, 3,3,5-trimethylcyclohexylsalicylate, 2-hydroxy-4-methoxybenzophenone, 2 Phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts, 3,3 '- (1,4-phenylenedimethylene) -bis (7,7-dimethyl-2-oxo-bicyclo- [2.2.1] hept- 1-yl-methanesulfonic acid) and its salts, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) -propane-1,3-dione, α- (2-oxoborn-3-ylidene) toluene-4-sulfonic acid and its salts, ethoxylated 4-aminobenzoic acid ethyl ester, 2-ethylhexyl 4-dimethylaminobenzoate, 2-ethylhexyl salicylate, isopentyl 4-methoxycinnamate, 2-ethylhexyl 4-methoxycinnamate, 2-hydroxy 4-methoxybenzophenone-5-sulfonic acid and its sodium salt, 3- (4'-methylbenzylidene) -D, L-camphor, 3-benzylidene-camphor, 4-isopropylbenzylsalicylate, 2,4,6-trianilino- (p-carbo-) 2'-ethylhexyl-1'-oxi) -1,3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of N - {(2 and 4) - [2-o xoborn-3-ylidenemethyl] benzyl} acrylamide. Very particularly preferred according to the invention are 2-hydroxy-4-methoxybenzophenone, 2-phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) -propane-1,3-dione, 4-methoxycinnamic acid 2-ethylhexyl ester and 3- (4'-methylbenzylidene) -D, L-camphor.

Preference is given to those UV filters whose molar extinction coefficient at the absorption maximum is above 15,000, in particular above 20,000.

Furthermore, it has been found that structurally similar UV filters in many cases, the water-insoluble compound in the teaching of the invention has the higher effect compared to such water-soluble compounds that differ from it by one or more additional ionic groups. In the context of the invention, water-insoluble are to be understood as meaning those UV filters which dissolve in water at 20 ° C. to not more than 1% by weight, in particular not more than 0.1% by weight. Furthermore, these compounds should be soluble in the usual cosmetic oil components at room temperature to at least 0.1, in particular at least 1 wt .-%). The use of water-insoluble UV filters may therefore be preferred according to the invention.

According to a further embodiment of the invention, preference is given to those UV filters which have a cationic group, in particular a quaternary ammonium group.

These UV filters have the general structure U-Q.

• – substituierte Benzophenone,
• – p-Aminobenzoesäureester,
• – Diphenylacrylsäureester,
• – Zimtsäureester,
• – Salicylsäureester,
• – Benzimidazole und
• – o-Aminobenzoesäureester.

The structural part U stands for a UV-absorbing group. This group can in principle be derived from the known UV filters which can be used in the cosmetics sector, in which a group, generally a hydrogen atom, of the UV filter is replaced by a cationic group Q, in particular having a quaternary amino function , Compounds from which the structural part U can derive are, for example

• Substituted benzophenones,
• P-aminobenzoic acid ester,
• - diphenylacrylic acid ester,
• - cinnamic acid ester,
• Salicylic acid ester,
• Benzimidazoles and
• O-aminobenzoic acid ester.

Structural parts U which are derived from cinnamic acid amide or from N, N-dimethylaminobenzoic acid amide are preferred according to the invention.

The structural parts U can in principle be selected such that the absorption maximum of the UV filters can be in both the UVA (315-400 nm) and in the UVB (280-315 nm) or in the UVC (<280 nm) range , UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.

Furthermore, the structural part U, also as a function of structural part Q, is preferably selected so that the molar extinction coefficient of the UV filter at the absorption maximum is above 15,000, in particular above 20,000.

The structural part Q preferably contains, as a cationic group, a quaternary ammonium group. This quaternary ammonium group can in principle be connected directly to the structural part U, so that the structural part U represents one of the four substituents of the positively charged nitrogen atom. Preferably, however, one of the four substituents on the positively charged nitrogen atom is a group, especially an alkylene group of 2 to 6 carbon atoms, which functions as a compound between the structural portion U and the positively charged nitrogen atom.

Advantageously, the group Q has the general structure - (CH ₂ ) _x -N ⁺ R ¹ R ² R ³ X ^- , in which x is an integer from 1 to 4, R ¹ and R ² independently of one another are C _{1 -4} alkyl groups, R ³ is a C _1-22 alkyl group or a benzyl group and X ^{- is} a physiologically acceptable anion. In the context of this general structure, x preferably represents the number 3, R ¹ and R ² each represent a methyl group and R ^{3 represents} either a methyl group or a saturated or unsaturated, linear or branched hydrocarbon chain having 8 to 22, in particular 10 to 18, carbon atoms.

Physiologically acceptable anions are, for example, inorganic anions such as halides, in particular chloride, bromide and fluoride, sulfate ions and phosphate ions and organic anions such as lactate, citrate, acetate, tartrate, methosulfate and tosylate.

Two preferred UV filters with cationic groups are the commercially available compounds cinnamic acid trimethyl ammonium chloride (Incroquat ^® UV-283) and Dodecyldimethylaminobenzamidopropyl-tosylate (Escalol ^® HP 610).

Of course, the teaching of the invention also includes the use of a combination of several UV filters. In the context of this embodiment, the combination of at least one water-insoluble UV filter with at least one UV filter with a cationic group is preferred.

The UV filters (I) are usually contained in the agents according to the invention in amounts of 0.1-5% by weight, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.

The compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J). Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C ₁ - to C ₄ -alkyl groups. The sodium salt is most preferred. The amounts used in the compositions according to the invention are preferably 0.05 to 10 wt .-%, based on the total agent, particularly preferably 0.1 to 5, and in particular 0.1 to 3 wt .-%.

In addition, it may prove advantageous if the compositions according to the invention contain penetration aids and / or swelling agents (M). These include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol ethers, for example propylene glycol monoethyl ether, carbonates, bicarbonates, Diols and triols, and especially 1,2-diols and 1,3-diols such as 1,2-propanediol, 1,2-pentanediol, 1,2-hexanediol, 1,2-dodecanediol, 1,3-propanediol, 1 , 6-hexanediol, 1,5-pentanediol, 1,4-butanediol.

Advantageously in the context of the invention, short-chain carboxylic acids (N) may additionally support the active substance complex (A). Short-chain carboxylic acids and their derivatives in the context of the invention are understood to mean carboxylic acids which may be saturated or unsaturated and / or straight-chain or branched or cyclic and / or aromatic and / or heterocyclic and have a molecular weight of less than 750. For the purposes of the invention, preference may be given to saturated or unsaturated straight-chain or branched carboxylic acids having a chain length of from 1 to 16 C atoms in the chain, very particular preference being given to those having a chain length of from 1 to 12 C atoms in the chain.

The short-chain carboxylic acids according to the invention may have one, two, three or more carboxy groups. Preferred within the meaning of the invention are carboxylic acids having a plurality of carboxy groups, in particular di- and tricarboxylic acids. The carboxy groups may be wholly or partly present as esters, acid anhydride, lactone, amide, imidic acid, lactam, lactim, dicarboximide, carbohydrazide, hydrazone, hydroxam, hydroxime, amidine, amidoxime, nitrile, phosphonic or phosphate ester. The carboxylic acids used according to the invention may of course be substituted along the carbon chain or the ring skeleton. The substituents of the carboxylic acids used according to the invention include, for example, C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, aryl, aralkyl and aralkenyl, hydroxymethyl, C 2 -C 8 -hydroxyalkyl, C 2 -C 8 -hydroxyalkenyl , Aminomethyl, C 2 -C 8 -aminoalkyl, cyano, formyl, oxo, thioxo, hydroxy, mercapto, amino, carboxy or imino groups. Preferred substituents are C 1 -C 8 alkyl, hydroxymethyl, hydroxy, amino and carboxy groups. Particularly preferred are substituents in position. Very particularly preferred substituents are hydroxy, alkoxy and amino groups, where the amino function may optionally be further substituted by alkyl, aryl, aralkyl and / or alkenyl radicals. Furthermore, preferred carboxylic acid derivatives are the phosphonic and phosphate esters.

• – Anlagerungsprodukte von 4 bis 30 Mol Ethylenoxid und/oder 0 bis 5 Mol Propylenoxid an lineare Fettalkohole mit 8 bis 22 C-Atomen, an Fettsäuren mit 12 bis 22 C-Atomen und an Alkylphenole mit 8 bis 15 C-Atomen in der Alkylgruppe,
• – C₁₂-C₂₂-Fettsäuremono- und -diester von Anlagerungsprodukten von 1 bis 30 Mol Ethylenoxid an Polyole mit 3 bis 6 Kohlenstoffatomen, insbesondere an Glycerin,
• – Ethylenoxid- und Polyglycerin-Anlagerungsprodukte an Methylglucosid-Fettsäureester, Fettsäurealkanolamide und Fettsäureglucamide,
• – C₈-C₂₂-Alkylmono- und -oligoglycoside und deren ethoxylierte Analoga, wobei Oligomerisierungsgrade von 1,1 bis 5, insbesondere 1,2 bis 2,0, und Glucose als Zuckerkomponente bevorzugt sind,
• – Gemische aus Alkyl-(oligo)-glucosiden und Fettalkoholen zum Beispiel das im Handel erhältliche Produkt Montanov^®68,
• – Anlagerungsprodukte von 5 bis 60 Mol Ethylenoxid an Rizinusöl und gehärtetes Rizinusöl,
• – Partialester von Polyolen mit 3–6 Kohlenstoffatomen mit gesättigten Fettsäuren mit 8 bis 22 C-Atomen,
• – Sterine. Als Sterine wird eine Gruppe von Steroiden verstanden, die am C-Atom 3 des Steroid-Gerüstes eine Hydroxylgruppe tragen und sowohl aus tierischem Gewebe (Zoosterine) wie auch aus pflanzlichen Fetten (Phytosterine) isoliert werden. Beispiele für Zoosterine sind das Cholesterin und das Lanosterin. Beispiele geeigneter Phytosterine sind Ergosterin, Stigmasterin und Sitosterin. Auch aus Pilzen und Hefen werden Sterine, die sogenannten Mykosterine, isoliert.
• – Phospholipide. Hierunter werden vor allem die Glucose-Phospolipide, die z. B. als Lecithine bzw. Phospahtidylcholine aus z. B. Eidotter oder Pflanzensamen (z. B. Sojabohnen) gewonnen werden, verstanden.
• – Fettsäureester von Zuckern und Zuckeralkoholen, wie Sorbit,
• – Polyglycerine und Polyglycerinderivate wie beispielsweise Polyglycerinpoly-12-hydroxystearat (Handelsprodukt Dehymuls^® PGPH),
• – Lineare und verzweigte Fettsäuren mit 8 bis 30 C – Atomen und deren Na-, K-, Ammonium-, Ca-, Mg- und Zn-Salze.

In a further preferred embodiment, the agents according to the invention may contain emulsifiers (F). Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion. Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions. An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants. The selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion. Emulsifiers which can be used according to the invention are, for example

• Addition products of from 4 to 30 mol of ethylene oxide and / or from 0 to 5 mol of propylene oxide onto linear fatty alcohols having from 8 to 22 carbon atoms, to fatty acids containing from 12 to 22 carbon atoms and to alkylphenols having from 8 to 15 carbon atoms in the alkyl group,
• C ₁₂ -C ₂₂ -fatty acid mono- and diesters of addition products of from 1 to 30 mol of ethylene oxide onto polyols having from 3 to 6 carbon atoms, in particular to glycerol,
• Ethylene oxide and polyglycerol addition products to methyl glucoside fatty acid esters, fatty acid alkanolamides and fatty acid glucamides,
• C ₈ -C ₂₂ -alkylmono- and -oligoglycosides and their ethoxylated analogues, preference being given to degrees of oligomerization of from 1.1 to 5, in particular from 1.2 to 2.0, and glucose as the sugar component,
• Glucosides mixtures of alkyl (oligo) and fatty alcohols, for example, the commercially available product ^® Montanov 68, -
• Adducts of 5 to 60 moles of ethylene oxide with castor oil and hydrogenated castor oil,
• Partial esters of polyols having 3-6 carbon atoms with saturated fatty acids having 8 to 22 C atoms,
• - sterols. Sterols are understood to mean a group of steroids which have a hydroxyl group on C-atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterols) and from vegetable fats (phytosterols). Examples of zoosterols are cholesterol and lanosterol. Examples of suitable phytosterols are ergosterol, stigmasterol and sitosterol. Mushrooms and yeasts are also used to isolate sterols, the so-called mycosterols.
• - Phospholipids. These include, above all, the glucose phospholipids, which are z. B. as lecithins or Phospahtidylcholine from z. Egg yolks or plant seeds (eg soybeans) are understood.
• Fatty acid esters of sugars and sugar alcohols, such as sorbitol,
• - polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate (commercial product Dehymuls ^® PGPH),
• - Linear and branched fatty acids with 8 to 30 C atoms and their Na, K, ammonium, Ca, Mg and Zn salts.

The agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.

The compositions according to the invention may preferably contain at least one nonionic emulsifier having an HLB value of 8 to 18. Nonionic emulsifiers with an HLB value of 10-15 may be particularly preferred according to the invention.

It has furthermore proven to be advantageous if, in addition to the polymer (s) from the group of cationic and / or amphoteric polymers, further polymers (G) are contained in the agents according to the invention. In a preferred embodiment, therefore, further polymers are added to the compositions according to the invention, both anionic and nonionic polymers having proven effective.

The anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups. Examples of anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid. The acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt. Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.

Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for all or some of the sulfonic acid group to be present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,

More preferably, the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid, which is available for example under the name Rheothik ^® 11-80 is commercially.

Within this embodiment, it may be preferable to use copolymers of at least one anionic monomer and at least one nonionic monomer. With regard to the anionic monomers, reference is made to the substances listed above. Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.

Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. A particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group is wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt is present. This copolymer may also be crosslinked, with crosslinking agents preferably polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylene-bisacrylamide are used. Such a polymer is in the commercial product Sepigel ^® 305 from SEPPIC. The use of this compound, which in addition to the polymer component contains a hydrocarbon mixture (C ₁₃ -C ₁₄ isoparaffin) and a nonionic emulsifier (laureth-7), has proved to be particularly advantageous within the scope of the teaching according to the invention.

Also sold under the name Simulgel ^® 600 as a compound with isohexadecane and polysorbate-80 Natriumacryloyldimethyltaurat copolymers have proved to be particularly effective according to the invention.

Likewise preferred anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ^® commercially.

Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers. A 1.9-decadienes crosslinked maleic acid-methyl copolymer available under the name Stabileze® ^® QM.

In another embodiment, the agents according to the invention may contain nonionic polymers (G4).

• – Vinylpyrrolidon/Vinylester-Copolymere, wie sie beispielsweise unter dem Warenzeichen Luviskol^® (BASF) vertrieben werden. Luviskol^® VA 64 und Luviskol^® VA 73, jeweils Vinylpyrrolidon/Vinylacetat-Copolymere, sind ebenfalls bevorzugte nichtionische Polymere.
• – Celluloseether, wie Hydroxypropylcellulose, Hydroxyethylcellulose und Methylhydroxypropylcellulose, wie sie beispielsweise unter den Warenzeichen Culminal^® und Benecel^® (AQUALON) und Natrosol^®-Typen (Hercules) vertrieben werden.
• – Stärke und deren Derivate, insbesondere Stärkeether, beispielsweise Structure^® XL (National Starch), eine multifunktionelle, salztolerante Stärke;
• – Schellack
• – Polyvinylpyrrolidone, wie sie beispielsweise unter der Bezeichnung Luviskol^® (BASF) vertrieben werden.
• – Siloxane. Diese Siloxane können sowohl wasserlöslich als auch wasserunlöslich sein. Geeignet sind sowohl flüchtige als auch nichtflüchtige Siloxane, wobei als nichtflüchtige Siloxane solche Verbindungen verstanden werden, deren Siedepunkt bei Normaldruck oberhalb von 200°C liegt. Bevorzugte Siloxane sind Polydialkylsiloxane, wie beispielsweise Polydimethylsiloxan, Polyalkylarylsiloxane, wie beispielsweise Polyphenylmethylsiloxan, ethoxylierte Polydialkylsiloxane sowie Polydialkylsiloxane, die Amin- und/oder Hydroxy-Gruppen enthalten.
• – Glycosidisch substituierte Silicone.

Suitable nonionic polymers are, for example:

• - Vinylpyrrolidone / vinyl ester copolymers, such as those sold under the trademark Luviskol ^® (BASF). Luviskol ^® VA 64 and Luviskol ^® VA 73, each vinylpyrrolidone / vinyl acetate copolymers, are also preferred nonionic polymers.
• - cellulose ethers such as hydroxypropyl cellulose, hydroxyethyl cellulose and methylhydroxypropyl cellulose, as for example under the trademark Culminal® ^® and Benecel ^® (AQUALON) and Natrosol ^® grades (Hercules) are distributed.
• - starch and its derivatives, in particular starch, such as Structure XL ^® (National Starch), a multifunctional, salt-tolerant starch;
• - shellac
• - polyvinylpyrrolidones, as for example under the name Luviskol ^® (BASF).
• - siloxanes. These siloxanes can be both water-soluble and water-insoluble. Both volatile and nonvolatile siloxanes are suitable, nonvolatile siloxanes being understood as meaning those compounds whose boiling point is above 200 ° C. under normal pressure. Preferred siloxanes are polydialkylsiloxanes, such as, for example, polydimethylsiloxane, polyalkylarylsiloxanes, such as, for example, polyphenylmethylsiloxane, ethoxylated polydialkylsiloxanes and polydialkylsiloxanes which contain amine and / or hydroxyl groups.
• - Glycosidically substituted silicones.

It is also possible according to the invention that the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.

The other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0.1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.

Another object of the present invention is a method for the treatment of keratinic fibers, in particular human hair, in which a hair treatment agent according to the invention applied to keratinous fibers and left there either until the next hair wash (so-called "leave-on" product) or after a contact time rinsed from 30 to 300 seconds (so-called "rinse-off" product) is.

The use of the agents according to the invention as shampoo or conditioner is preferred. A second subject of the invention is therefore a method for the treatment of skin and keratinic fibers, in which a composition according to the invention applied to the skin and / or hair, distributed and rinsed with water after a contact time of a few seconds to 45 minutes.

A further subject of the invention is the use of a composition according to the invention for reducing the re-soiling of skin and / or keratinic fibers.

A further subject of the invention is the use of a composition according to the invention for the care and conditioning of skin and / or keratin fibers.

Another subject of the invention is the use of a composition according to the invention for the restructuring of keratinic fibers.

A further subject of the invention is the use of a composition according to the invention for improving the washout stability of dyed keratinic fibers.

With regard to preferred methods and uses according to the invention, what has been said about the agents according to the invention applies mutatis mutandis.

QUOTES INCLUDE IN THE DESCRIPTION

This list of the documents listed by the applicant has been generated automatically and is included solely for the better information of the reader. The list is not part of the German patent or utility model application. The DPMA assumes no liability for any errors or omissions.

Cited patent literature

• DE 4413686 [0032, 0035]
• DE 3725030 A [0054]
• WO 92/13829 [0099]

Claims (10)

Hair treatment composition containing - based on its weight - a. at least 0.01% by weight of one or more oils obtained from the seeds of the capercaillie (Calodendrum capense; Yangu), b. 0.1 to 10.0% by weight of at least one polymeric quaternary ammonium compound, c. an aqueous carrier. Hair treatment composition according to claim 1, characterized in that it contains 0.05 to 10 wt .-%, preferably 0.075 to 7.5 wt .-%, more preferably 0.1 to 5 wt .-%, particularly preferably 0.15 to 2, 5 wt .-% and in particular 0.2 to 1 wt .-% Yangu oil contains. Hair treatment composition according to one of claims 1 or 2, characterized in that it contains 0.15 to 7.5 wt .-%, more preferably 0.2 to 5 wt .-%, particularly preferably 0.25 to 2.5 wt .-% and in particular from 0.3 to 2% by weight of one or more polymeric quaternary ammonium compounds from the group - Poly (methacryloyloxyethyltrimethylammoniumverbindungen) and / or Quaternized cellulose derivatives, in particular Polyquaternium 10 and / or Polyquaternium 67, and / or Cationic guar derivatives and / or - Chitosan and / or Polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or - Copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acrylate and methacrylate and / or - Vinylpyrrolidone-Vinylimidazoliummethochlorid copolymers and / or Quaternized polyvinyl alcohol and / or Polyquaternium 2 and / or Polyquaternium-7 and / or Polyquaternium-16 and / or - Polyquaternium 17 and / or - Polyquaternium 18 and / or - Polyquaternium 24 and / or - Polyquaternium 27 contains. Hair treatment composition according to one of claims 1 to 3, characterized in that it contains 0.15 to 7.5 wt .-%, more preferably 0.2 to 5 wt .-%, particularly preferably 0.25 to 2.5 wt .-% and in particular from 0.3 to 2% by weight of at least one protein hydrolyzate of animal origin, preferred agents from 0.15 to 7.5% by weight, more preferably from 0.2 to 5% by weight, particularly preferably from 0.25 to Contains 2.5 wt .-% and in particular 0.3 to 2 wt .-% keratin hydrolyzate (s). Hair treatment composition according to one of claims 1 to 4, characterized in that it is 0.02 to 2.5 wt .-%, preferably 0.05 to 1.5 wt .-%, particularly preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine contains. A process for the treatment of skin and keratinic fibers, characterized in that a composition according to any one of claims 1 to 5 applied to the skin and / or hair, distributed and rinsed after a contact time of a few seconds to 45 minutes with water. Use of a composition according to any one of claims 1 to 5 for reducing the re-soiling of skin and / or keratinic fibers. Use of a composition according to any one of claims 1 to 5 for the care and conditioning of skin and / or keratinic fibers. Use of a composition according to any one of claims 1 to 5 for the restructuring of keratinic fibers. Use of a composition according to any one of claims 1 to 5 for improving the washing-out resistance of dyed keratinic fibers.